Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 3.4.24.86 - ADAM 17 endopeptidase

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Acidosis
Hypercapnia attenuates ventilator-induced lung injury via a disintegrin and metalloprotease-17.
Acute Kidney Injury
ADAM17 substrate release in proximal tubule drives kidney fibrosis.
Novel Evidence of Acute Kidney Injury in COVID-19.
Acute Lung Injury
Effects of tumor necrosis factor-a converting enzyme inhibition on acute lung injury induced by endotoxin in the rat.
Leukocyte ADAM17 regulates acute pulmonary inflammation.
adam 17 endopeptidase deficiency
ADAM10 and ADAM17 regulate EGFR, c-Met and TNF RI signalling in liver regeneration and fibrosis.
ADAM17 deficiency by mature neutrophils has differential effects on L-selectin shedding.
Adam17 Deficiency Promotes Atherosclerosis by Enhanced TNFR2 Signaling in Mice.
ADAM17 Deficiency Protects against Pulmonary Emphysema.
ADAM17 deletion in thymic epithelial cells alters aire expression without affecting T cell developmental progression.
ADAM17 is essential for ectodomain shedding of the EGF-receptor ligand amphiregulin.
Cell-Specific Functions of ADAM17 Regulate the Progression of Thoracic Aortic Aneurysm.
Cytokine secretion and NK cell activity in human ADAM17 deficiency.
Epithelial Cell-Derived a Disintegrin and Metalloproteinase-17 Confers Resistance to Colonic Inflammation Through EGFR Activation.
Isoform-specific contribution of protein kinase C to prion processing.
Macrophage ADAM17 deficiency augments CD36-dependent apoptotic cell uptake and the linked anti-inflammatory phenotype.
Shedding of the MER tyrosine kinase receptor is mediated by ADAM17 through a pathway involving reactive oxygen species, protein kinase {delta}, and P38 map kinase.
Short-term TNF? shedding is independent of cytoplasmic phosphorylation or furin cleavage of ADAM17.
Smooth muscle cells relay acute pulmonary inflammation via distinct ADAM17/ErbB axes.
Structural and Functional Analyses of the Shedding Protease ADAM17 in HoxB8-Immortalized Macrophages and Dendritic-like Cells.
The ADAM17 Protease Promotes Tobacco Smoke Carcinogen-induced Lung Tumourigenesis.
The role of metalloproteinase ADAM17 in regulating ICOS ligand-mediated humoral immune responses.
The Threshold Effect: Lipopolysaccharide-Induced Inflammatory Responses in Primary Macrophages Are Differentially Regulated in an iRhom2-Dependent Manner.
Vascular ADAM17 (a Disintegrin and Metalloproteinase Domain 17) Is Required for Angiotensin II/?-Aminopropionitrile-Induced Abdominal Aortic Aneurysm.
adam10 endopeptidase deficiency
ADAM10 and ADAM17 regulate EGFR, c-Met and TNF RI signalling in liver regeneration and fibrosis.
Differentially regulated GPVI ectodomain shedding by multiple platelet-expressed proteinases.
Part-time alpha-secretases: the functional biology of ADAM 9, 10 and 17.
Adenocarcinoma
Targeting ADAM17 inhibits human colorectal adenocarcinoma progression and tumor-initiating cell frequency.
Adenocarcinoma of Lung
Adam17, a Target of Mir-326, Promotes Emt-Induced Cells Invasion in Lung Adenocarcinoma.
Lentivirus-mediated disintegrin and metalloproteinase 17 RNA interference reversed the acquired resistance to gefitinib in lung adenocarcinoma cells in vitro.
The ADAM17 Protease Promotes Tobacco Smoke Carcinogen-induced Lung Tumourigenesis.
Albuminuria
Daily exercise training protects against albuminuria and angiotensin converting enzyme 2 shedding in db/db diabetic mice.
Rosiglitazone treatment of type 2 diabetic db/db mice attenuates urinary albumin and angiotensin converting enzyme 2 excretion.
Alzheimer Disease
A rare loss-of-function variant of ADAM17 is associated with late-onset familial Alzheimer disease.
ADAM-17: the enzyme that does it all.
Coordinated expression of beta-amyloid precursor protein and the putative beta-secretase BACE and alpha-secretase ADAM10 in mouse and human brain.
ERK1-independent ?-secretase cut of ?-amyloid precursor protein via M1 muscarinic receptors and PKC?/?.
Quercetin stimulates the non-amyloidogenic pathway via activation of ADAM10 and ADAM17 gene expression in aluminum chloride-induced Alzheimer's disease rat model.
Reduced neuronal co-localisation of nardilysin and the putative alpha-secretases ADAM10 and ADAM17 in Alzheimer's disease and Down syndrome brains.
The Distinct Role of ADAM17 in APP Proteolysis and Microglial Activation Related to Alzheimer's Disease.
The relationship between ADAM17 promoter polymorphisms and sporadic Alzheimer's disease in a Northern Chinese Han population.
Aneurysm
Factor XII blockade inhibits aortic dilatation in angiotensin II-infused apolipoprotein E-deficient mice.
Transcriptional Profiling and Network Analysis of the Murine Angiotensin II-Induced Abdominal Aortic Aneurysm.
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Circulating ADAM17 Level Reflects Disease Activity in Proteinase-3 ANCA-Associated Vasculitis.
Aortic Aneurysm, Abdominal
Analysis of ADAM17 polymorphisms and susceptibility to sporadic abdominal aortic aneurysm.
Proteolytically active ADAM10 and ADAM17 carried on membrane microvesicles in human abdominal aortic aneurysms.
Vascular ADAM17 (a Disintegrin and Metalloproteinase Domain 17) Is Required for Angiotensin II/?-Aminopropionitrile-Induced Abdominal Aortic Aneurysm.
Aortic Aneurysm, Thoracic
Cell-Specific Functions of ADAM17 Regulate the Progression of Thoracic Aortic Aneurysm.
Elevation of ADAM10, ADAM17, MMP-2 and MMP-9 expression with media degeneration features CaCl2-induced thoracic aortic aneurysm in a rat model.
Arthritis
Differential effects between marimastat, a TNF-alpha converting enzyme inhibitor, and anti-TNF-alpha antibody on murine models for sepsis and arthritis.
Emerging roles of rhomboid-like pseudoproteases in inflammatory and innate immune responses.
Arthritis, Rheumatoid
A disintegrin and metalloprotease-17 and galectin-9 are important regulators of local 4-1BB activity and disease outcome in rheumatoid arthritis.
A transforming Src mutant increases the bioavailability of EGFR ligands via stimulation of the cell-surface metalloproteinase ADAM17.
ADAM-17 is expressed on rheumatoid arthritis fibroblast-like synoviocytes and regulates proinflammatory mediator expression and monocyte adhesion.
ADAM-17: the enzyme that does it all.
ADAM17 Genetic Variants and the Response of TNF-? Inhibitor in Rheumatoid Arthritis Patients.
Design strategies for the identification of MMP-13 and Tace inhibitors.
Effect of DPC 333 [(2R)-2-{(3R)-3-amino-3-[4-(2-methylquinolin-4-ylmethoxy)phenyl]-2-oxopyrrolidin-1-yl}-N-hydroxy-4-methylpentanamide], a human tumor necrosis factor alpha-converting enzyme inhibitor, on the disposition of methotrexate: a transporter-based drug-drug interaction case study.
Glycosylation of a disintegrin and metalloprotease 17 affects its activity and inhibition.
Identification of a selectivity determinant for inhibition of tumor necrosis factor-alpha converting enzyme by comparative modeling.
Macrophage activity assessed by soluble CD163 in early rheumatoid arthritis: association with disease activity but different response patterns to synthetic and biologic DMARDs.
Novel functions of inactive rhomboid proteins in immunity and disease.
Prediction of novel and selective TNF-alpha converting enzyme (TACE) inhibitors and characterization of correlative molecular descriptors by machine learning approaches.
Reduction of Serum ADAM17 Level Accompanied with Decreased Cytokines after Abatacept Therapy in Patients with Rheumatoid Arthritis.
Role of ADAM17, p38 MAPK, cathepsins, and proteasome pathway in the synthesis and shedding of fractalkine/CX3CL1 in rheumatoid arthritis.
Targeting the sheddase activity of ADAM17 by an anti-ADAM17 antibody D1(A12) inhibits head and neck squamous cell carcinoma cell proliferation and motility via blockage of bradykinin induced HERs transactivation.
Asthma
Abnormal ADAM17 expression causes airway fibrosis in chronic obstructive asthma.
ACE2 expression is elevated in airway epithelial cells from older and male healthy individuals but reduced in asthma.
Glucocorticoids induce the production of the chemoattractant CCL20 in airway epithelium.
The xenoestrogens biphenol-A and nonylphenol differentially regulate metalloprotease-mediated shedding of EGFR ligands.
Astrocytoma
Carnosic acid suppresses the production of amyloid-? 1-42 and 1-43 by inducing an ?-secretase TACE/ADAM17 in U373MG human astrocytoma cells.
Atherosclerosis
A Disintegrin and Metalloproteases (ADAMs) in Cardiovascular, Metabolic and Inflammatory Diseases: Aspects for Theranostic Approaches.
A disintegrin and metalloproteinase 17 (ADAM17) mediates epidermal growth factor receptor transactivation by angiotensin II on hepatic stellate cells.
A score including ADAM17 substrates correlates to recurring cardiovascular event in subjects with atherosclerosis.
ADAM-9, ADAM-15, and ADAM-17 are upregulated in macrophages in advanced human atherosclerotic plaques in aorta and carotid and femoral arteries--Tampere vascular study.
Adam17 Deficiency Promotes Atherosclerosis by Enhanced TNFR2 Signaling in Mice.
ADAM17: A Molecular Switch to Control TNFR2 During Atherogenesis In Vivo.
Association between ADAM17 Promoter Polymorphisms and Ischemic Stroke in a Chinese Population.
Cilostazol inhibits interleukin-1-induced ADAM17 expression through cAMP independent signaling in vascular smooth muscle cells.
Contrasting effects of myeloid and endothelial ADAM17 on atherosclerosis development.
Gene silencing of TACE enhances plaque stability and improves vascular remodeling in a rabbit model of atherosclerosis.
Increased ADAM17 mRNA expression and activity is associated with atherosclerosis resistance in LDL-receptor deficient mice.
MiR-152 reduces human umbilical vein endothelial cell proliferation and migration by targeting ADAM17.
Role of ADAM17 in kidney disease.
The role of ADAM17 in metabolic inflammation.
The Role of iRhom2 in Metabolic and Cardiovascular-Related Disorders.
Vascular Induction of a Disintegrin and Metalloprotease 17 by Angiotensin II Through Hypoxia Inducible Factor 1?
[The two sides of ADAM17 in inflammation: implications in atherosclerosis and obesity]
Autoimmune Diseases
ADAM17 at the interface between inflammation and autoimmunity.
Distance dependent shedding of IL-6R.
Identification of a selectivity determinant for inhibition of tumor necrosis factor-alpha converting enzyme by comparative modeling.
Macrophage activity assessed by soluble CD163 in early rheumatoid arthritis: association with disease activity but different response patterns to synthetic and biologic DMARDs.
New Insights Into ADAMs Regulation of the GRO-?/CXCR2 System: Focus on Sjögren's Syndrome.
Novel functions of inactive rhomboid proteins in immunity and disease.
Bacteremia
Targeting ADAM17 in leukocytes increases neutrophil recruitment and reduces bacterial spread during polymicrobial sepsis.
Bacterial Infections
ADAM17 activation in circulating neutrophils following bacterial challenge impairs their recruitment.
Brain Injuries
Doxycycline reduces mortality and injury to the brain and cochlea in experimental pneumococcal meningitis.
Brain Injuries, Traumatic
Specific inhibition of ADAM17/TACE promotes neurogenesis in the injured motor cortex.
Brain Neoplasms
ADAM17 promotes breast cancer cell malignant phenotype through EGFR-PI3K-AKT activation.
Inhibition of ADAM17 reduces hypoxia-induced brain tumor cell invasiveness.
Breast Neoplasms
A novel bispecific single-chain antibody for ADAM17 and CD3 induces T-cell-mediated lysis of prostate cancer cells.
A-Disintegrin and Metalloproteinase (ADAM) 17 Enzymatically Degrades Interferon-gamma.
ADAM-17 expression in breast cancer correlates with variables of tumor progression.
ADAM-17 predicts adverse outcome in patients with breast cancer.
ADAM-17: a novel therapeutic target for triple negative breast cancer.
ADAM12 and ADAM17 Gene Expression in Laser-capture Microdissected and Non-microdissected Breast Tumors.
ADAM17 promotes breast cancer cell malignant phenotype through EGFR-PI3K-AKT activation.
ADAM17 promotes glioma cell malignant phenotype.
ADAM17-overexpressing breast cancer cells selectively targeted by antibody-toxin conjugates.
ADAM17-siRNA inhibits MCF-7 breast cancer through EGFR-PI3K-AKT activation.
ADAM22 as a prognostic and therapeutic drug target in the treatment of endocrine-resistant breast cancer.
Diallyl trisulfide, a chemopreventive agent from Allium vegetables, inhibits alpha-secretases in breast cancer cells.
Discovery of an enzyme and substrate selective inhibitor of ADAM10 using an exosite-binding glycosylated substrate.
Effects of ADAM10 and ADAM17 Inhibitors on Natural Killer Cell Expansion and Antibody-dependent Cellular Cytotoxicity Against Breast Cancer Cells
HER2 phosphorylation is maintained by a PKB negative feedback loop in response to anti-HER2 herceptin in breast cancer.
Human breast cancer-associated fibroblasts enhance cancer cell proliferation through increased TGF-? cleavage by ADAM17.
Identification of Novel MicroRNAs as Promising Therapeutics for SARS-CoV-2 by Regulating the EGFR-ADAM17 Axis: An In Silico Analysis.
Lentiviral CRISPR-guided RNA library screening identified Adam17 as an upstream negative regulator of Procr in mammary epithelium.
miR-221/222 control luminal breast cancer tumor progression by regulating different targets.
Modulation of gene expression in human central nervous system tumors under methionine deprivation-induced stress.
Nectin-4, a new serological breast cancer marker, is a substrate for tumor necrosis factor-alpha-converting enzyme (TACE)/ADAM-17.
Post-transcriptional up-regulation of ADAM17 upon epidermal growth factor receptor activation and in breast tumors.
Regulation of Platelet-Derived ADAM17: A Biomarker Approach for Breast Cancer?
Short hairpin RNA-mediated gene silencing of ADAM17 inhibits the growth of breast cancer MCF?7 cells in vitro and in vivo and its mechanism of action.
Targeting TACE-dependent EGFR ligand shedding in breast cancer.
The role of ADAM17 in tumorigenesis and progression of breast cancer.
The soluble nectin-4 ecto-domain promotes breast cancer induced angiogenesis via endothelial Integrin-?4.
The xenoestrogens biphenol-A and nonylphenol differentially regulate metalloprotease-mediated shedding of EGFR ligands.
Tumor necrosis factor-alpha-converting enzyme activities and tumor-associated macrophages in breast cancer.
CADASIL
Mechanistic insights into a TIMP3-sensitive pathway constitutively engaged in the regulation of cerebral hemodynamics.
Candidiasis
IL-1{beta} and ADAM17 are central regulators of {beta}-defensin expression in Candida esophagitis.
Carcinogenesis
A transforming Src mutant increases the bioavailability of EGFR ligands via stimulation of the cell-surface metalloproteinase ADAM17.
ADAM17 and NF-?B p65 form a positive feedback loop that facilitates human esophageal squamous cell carcinoma cell viability.
ADAM17 is a tumor promoter and therapeutic target in Western diet-associated colon cancer.
ADAM17 is overexpressed in non-small cell lung cancer and its expression correlates with poor patient survival.
ADAM17 is required for EGF-R-induced intestinal tumors via IL-6 trans-signaling.
ADAM17 regulates epidermal growth factor receptor expression through the activation of Notch1 in non-small cell lung cancer.
ADAM17-mediated CD44 cleavage promotes orasphere formation or stemness and tumorigenesis in HNSCC.
EGF Receptor Is Required for KRAS-Induced Pancreatic Tumorigenesis.
Hepatocyte specific TIMP3 expression prevents diet dependent fatty liver disease and hepatocellular carcinoma.
Interleukin-11-driven gastric tumourigenesis is independent of trans-signalling.
MicroRNA-122, a tumor suppressor microRNA that regulates intrahepatic metastasis of hepatocellular carcinoma.
Multiple Acquired Renal Carcinoma Tumor Capabilities Abolished upon Silencing of ADAM17.
Mutagenesis of the ADAM17-phosphatidylserine-binding motif leads to embryonic lethality in mice.
Prognostic value of ADAM17 in human gastric cancer.
Sheddase Activity of Tumor Necrosis Factor-{alpha} Converting Enzyme Is Increased and Prognostically Valuable in Head and Neck Cancer.
TACE is required for the activation of the EGFR by TGF-alpha in tumors.
Tetraspanin CD9 interacts with ?-secretase to enhance its oncogenic function in pancreatic cancer.
The ADAM17 Protease Promotes Tobacco Smoke Carcinogen-induced Lung Tumourigenesis.
The cytosolic domain of protein-tyrosine kinase 7 (PTK7), generated from sequential cleavage by a disintegrin and metalloprotease 17 (ADAM17) and ?-secretase, enhances cell proliferation and migration in colon cancer cells.
The role of ADAM17 in tumorigenesis and progression of breast cancer.
Upregulation of polycistronic microRNA-143 and microRNA-145 in colonocytes suppresses colitis and inflammation-associated colon cancer.
Carcinoma
A disintegrin and metalloproteinase 17 mRNA and protein expression in esophageal squamous cell carcinoma, as well as its clinicopathological factors and prognosis.
A novel marker ADAM17 for clear cell renal cell carcinomas: Implication for patients' prognosis.
ADAM-17 associated with CD44 cleavage and metastasis in oral squamous cell carcinoma.
ADAM-17 expression in breast cancer correlates with variables of tumor progression.
ADAM-17 expression is enhanced by FoxM1 and is a poor prognostic sign in gastric carcinoma.
ADAM-17 over-expression in gallbladder carcinoma correlates with poor prognosis of patients.
ADAM17 and NF-?B p65 form a positive feedback loop that facilitates human esophageal squamous cell carcinoma cell viability.
ADAM17 is associated with EMMPRIN and predicts poor prognosis in patients with uterine cervical carcinoma.
ADAM17 mediates OSCC development in an orthotopic murine model.
ADAM17 promotes epithelial-mesenchymal transition via TGF-?/Smad pathway in gastric carcinoma cells.
ADAM17 silencing in mouse colon carcinoma cells: the effect on tumoricidal cytokines and angiogenesis.
Autophagy regulates cisplatin-induced stemness and chemoresistance via the upregulation of CD44, ABCB1 and ADAM17 in oral squamous cell carcinoma.
Expression and clinical significance of ADAM17 protein in esophageal squamous cell carcinoma.
Involvement of NF-kappaB-mediated maturation of ADAM-17 in the invasion of oral squamous cell carcinoma.
Mass spectrometry-based proteomics revealed Glypican-1 as a novel ADAM17 substrate.
MicroRNA-145 Targets the Metalloprotease ADAM17 and Is Suppressed in Renal Cell Carcinoma Patients.
MicroRNA-224, negatively regulated by c-jun, inhibits growth and epithelial-to-mesenchymal transition phenotype via targeting ADAM17 in oral squamous cell carcinoma.
MiR-338-3p inhibits cell migration and invasion in human hypopharyngeal cancer via downregulation of ADAM17.
Soluble Form of the (Pro)Renin Receptor Generated by Intracellular Cleavage by Furin Is Secreted in Plasma.
Targeting the sheddase activity of ADAM17 by an anti-ADAM17 antibody D1(A12) inhibits head and neck squamous cell carcinoma cell proliferation and motility via blockage of bradykinin induced HERs transactivation.
The disintegrin domain of ADAM17 antagonises fibroblast?carcinoma cell interactions.
The disintegrin-metalloproteinases ADAM10 and ADAM17 are upregulated in cutaneous squamous cell carcinomas.
Therapeutic potential of ADAM17 modulation in gastric cancer through regulation of the EGFR and TNF-? signalling pathways.
Up-regulated expression of ADAM17 in human colon carcinoma: co-expression with EGFR in neoplastic and endothelial cells.
[Clinicopathological and prognostic significance of the expression of ADAM17 mRNA and protein in esophageal squamous cell carcinoma].
[Inhibition of proliferation, adhesion and invasion ability of human lung carcinoma cell A549 by tumor necrosis factor-alpha converting enzyme (TACE)]
Carcinoma, Hepatocellular
ADAM17 mediates hypoxia-induced drug resistance in hepatocellular carcinoma cells through activation of EGFR/PI3K/Akt pathway.
ADAM17 mRNA expression and pathological features of hepatocellular carcinoma.
ADAM17 promotes cell migration and invasion through the integrin ?1 pathway in hepatocellular carcinoma.
ADAM17 promotes the invasion of hepatocellular carcinoma via upregulation MMP21.
Effects of pro-inflammatory cytokines on the production of soluble fractalkine and ADAM17 by HepG2 cells.
Enzymatic inhibition of MICA sheddase ADAM17 by lomofungin in hepatocellular carcinoma cells.
Expression of miR-224, miR-145, and their putative target ADAM17 in hepatocellular carcinoma.
GPR50 Promotes Hepatocellular Carcinoma Progression via the Notch Signaling Pathway through Direct Interaction with ADAM17.
HNF-4? inhibits hepatocellular carcinoma cell proliferation through mir-122-adam17 pathway.
Inhibition of hepatocellular carcinoma cell proliferation, migration, and invasion by a disintegrin and metalloproteinase-17 inhibitor TNF484.
Inhibition of the EGF receptor blocks autocrine growth and increases the cytotoxic effects of doxorubicin in rat hepatoma cells: role of reactive oxygen species production and glutathione depletion.
MicroRNA-122, a tumor suppressor microRNA that regulates intrahepatic metastasis of hepatocellular carcinoma.
MicroRNA-145 inhibits cell proliferation by directly targeting ADAM17 in hepatocellular carcinoma.
MicroRNA-3163 targets ADAM-17 and enhances the sensitivity of hepatocellular carcinoma cells to molecular targeted agents.
miR-145 suppresses cell invasion in hepatocellular carcinoma cells: miR-145 targets ADAM17.
Novel ADAM-17 inhibitor ZLDI-8 enhances the in vitro and in vivo chemotherapeutic effects of Sorafenib on hepatocellular carcinoma cells.
Novel ADAM-17 inhibitor ZLDI-8 inhibits the metastasis of hepatocellular carcinoma by reversing epithelial-mesenchymal transition in vitro and in vivo.
Role of ADAM17 in invasion and migration of CD133-expressing liver cancer stem cells after irradiation.
Carcinoma, Non-Small-Cell Lung
ADAM17 is overexpressed in non-small cell lung cancer and its expression correlates with poor patient survival.
ADAM17 regulates epidermal growth factor receptor expression through the activation of Notch1 in non-small cell lung cancer.
ADAM17 silencing suppresses the migration and invasion of non-small cell lung cancer.
Estrogen upregulates MICA/B expression in human non-small cell lung cancer through the regulation of ADAM17.
Savior or not: ADAM17 inhibitors overcome radiotherapy-resistance in non-small cell lung cancer.
Secretome Signature Identifies ADAM17 as Novel Target for Radiosensitization of Non-Small Cell Lung Cancer.
Carcinoma, Renal Cell
A novel marker ADAM17 for clear cell renal cell carcinomas: Implication for patients' prognosis.
Inhibition of ADAM-17 more effectively down-regulates the Notch pathway than that of ?-secretase in renal carcinoma.
MicroRNA-145 Targets the Metalloprotease ADAM17 and Is Suppressed in Renal Cell Carcinoma Patients.
Multiple Acquired Renal Carcinoma Tumor Capabilities Abolished upon Silencing of ADAM17.
Predictive values of Notch signalling in renal carcinoma.
Carcinoma, Squamous Cell
Mass spectrometry-based proteomics revealed Glypican-1 as a novel ADAM17 substrate.
Targeting the sheddase activity of ADAM17 by an anti-ADAM17 antibody D1(A12) inhibits head and neck squamous cell carcinoma cell proliferation and motility via blockage of bradykinin induced HERs transactivation.
The disintegrin-metalloproteinases ADAM10 and ADAM17 are upregulated in cutaneous squamous cell carcinomas.
Cardiomegaly
A disintegrin and metalloproteinase 17 (ADAM17) mediates epidermal growth factor receptor transactivation by angiotensin II on hepatic stellate cells.
A Reduction in ADAM17 Expression Is Involved in the Protective Effect of the PPAR-? Activator Fenofibrate on Pressure Overload-Induced Cardiac Hypertrophy.
Deleting Vascular ADAM17 Sheds New Light on Hypertensive Cardiac Hypertrophy.
Endothelial deletion of ADAM17 in mice results in defective remodeling of the semilunar valves and cardiac dysfunction in adults.
MiR-26a-5p alleviates cardiac hypertrophy and dysfunction via targeting ADAM17.
Rutaecarpine prevents hypertensive cardiac hypertrophy involving the inhibition of Nox4-ROS-ADAM17 pathway.
Tumor necrosis factor-alpha-converting enzyme is a key regulator of agonist-induced cardiac hypertrophy and fibrosis.
Upregulation of Nox4 Promotes Angiotensin II-Induced Epidermal Growth Factor Receptor Activation and Subsequent Cardiac Hypertrophy by Increasing ADAM17 Expression.
Cardiomyopathies
A Disintegrin and Metalloprotease-17 Regulates Pressure Overload-Induced Myocardial Hypertrophy and Dysfunction Through Proteolytic Processing of Integrin ?1.
Alterations of the renin angiotensin system in human end-stage heart failure before and after mechanical cardiac unloading by LVAD support.
Altered expression of disintegrin metalloproteinases and their inhibitor in human dilated cardiomyopathy.
Cardiomyocyte A Disintegrin And Metalloproteinase 17 (ADAM17) Is Essential in Post-Myocardial Infarction Repair by Regulating Angiogenesis.
Cardiomyopathy, Dilated
A Disintegrin and Metalloprotease-17 Regulates Pressure Overload-Induced Myocardial Hypertrophy and Dysfunction Through Proteolytic Processing of Integrin ?1.
Alterations of the renin angiotensin system in human end-stage heart failure before and after mechanical cardiac unloading by LVAD support.
Altered expression of disintegrin metalloproteinases and their inhibitor in human dilated cardiomyopathy.
Tumor necrosis factor-alpha-converting enzyme and tumor necrosis factor-alpha in human dilated cardiomyopathy.
Cardiomyopathy, Hypertrophic
A Disintegrin and Metalloprotease-17 Regulates Pressure Overload-Induced Myocardial Hypertrophy and Dysfunction Through Proteolytic Processing of Integrin ?1.
Altered expression of disintegrin metalloproteinases and their inhibitor in human dilated cardiomyopathy.
Cardiovascular Diseases
Cilostazol inhibits interleukin-1-induced ADAM17 expression through cAMP independent signaling in vascular smooth muscle cells.
Contribution of ADAM17 and related ADAMs in cardiovascular diseases.
Role of ADAM17 in kidney disease.
Vascular Induction of a Disintegrin and Metalloprotease 17 by Angiotensin II Through Hypoxia Inducible Factor 1?
Cholestasis
Liver protective effect of ursodeoxycholic acid includes regulation of ADAM17 activity.
Chorioamnionitis
Tumour necrosis factor-alpha converting enzyme in human gestational tissues from pregnancies complicated by chorioamnionitis.
Chronic Kidney Disease-Mineral and Bone Disorder
ADAM17, a New Player in the Pathogenesis of Chronic Kidney Disease-Mineral and Bone Disorder.
Classical Swine Fever
ADAM17 is an essential attachment factor for classical swine fever virus.
Coinfection
ADAM17 silencing by adenovirus encoding miRNA-embedded siRNA revealed essential signal transduction by angiotensin II in vascular smooth muscle cells.
Colitis
Epithelial Cell-Derived a Disintegrin and Metalloproteinase-17 Confers Resistance to Colonic Inflammation Through EGFR Activation.
Implication of TNF-alpha convertase (TACE/ADAM17) in inducible nitric oxide synthase expression and inflammation in an experimental model of colitis.
MyD88 signaling in nonhematopoietic cells protects mice against induced colitis by regulating specific EGF receptor ligands.
The enhanced susceptibility of ADAM-17 hypomorphic mice to DSS-induced colitis is not ameliorated by loss of RIPK3, revealing an unexpected function of ADAM-17 in necroptosis.
TNF? cleavage beyond TACE/ADAM17: matrix metalloproteinase 13 is a potential therapeutic target in sepsis and colitis.
Colitis, Ischemic
Human colonic myocytes are involved in postischemic inflammation through ADAM17-dependent TNFalpha production.
Colitis, Ulcerative
In situ evidence of involvement of Schwann cells in ulcerative colitis: autocrine and paracrine signaling by A disintegrin and metalloprotease-17-mediated tumor necrosis factor alpha production.
Colonic Neoplasms
ADAM-17/FHL2 colocalisation suggests interaction and role of these proteins in colorectal cancer.
ADAM17 Activity and IL-6 Trans-Signaling in Inflammation and Cancer.
ADAM17 is a tumor promoter and therapeutic target in Western diet-associated colon cancer.
Functional Characterization of Colon Cancer-Associated Mutations in ADAM17: Modifications in the Pro-Domain Interfere with Trafficking and Maturation.
HPP1 Ectodomain Shedding is Mediated by ADAM17 and is Necessary for Tumor Suppression in Colon Cancer.
Nox1 promotes colon cancer cell metastasis via activation of the ADAM17 pathway.
The cytosolic domain of protein-tyrosine kinase 7 (PTK7), generated from sequential cleavage by a disintegrin and metalloprotease 17 (ADAM17) and ?-secretase, enhances cell proliferation and migration in colon cancer cells.
Upregulation of polycistronic microRNA-143 and microRNA-145 in colonocytes suppresses colitis and inflammation-associated colon cancer.
Colorectal Neoplasms
A novel inhibitor of ADAM17 sensitizes colorectal cancer cells to 5-Fluorouracil by reversing Notch and epithelial-mesenchymal transition in vitro and in vivo.
Chemotherapy-induced activation of ADAM-17: a novel mechanism of drug resistance in colorectal cancer.
Expression of Migration-Related Genes in Human Colorectal Cancer and Activity of a Disintegrin and Metalloproteinase 17.
HPP1 Ectodomain Shedding is Mediated by ADAM17 and is Necessary for Tumor Suppression in Colon Cancer.
Knockdown of ADAM17 inhibits cell proliferation and increases oxaliplatin sensitivity in HCT-8 colorectal cancer through EGFR-PI3K-AKT activation.
MiR-222 modulates multidrug resistance in human colorectal carcinoma by down-regulating ADAM-17.
Nox1 promotes colon cancer cell metastasis via activation of the ADAM17 pathway.
Relation between Tetraspanin- Associated and Tetraspanin- Non- Associated Exosomal Proteases and Metabolic Syndrome in Colorectal Cancer Patients
Serum levels of ADAM10, ADAM12, ADAM17 AND ADAM28 in colorectal cancer patients.
Targeting ADAM17 inhibits human colorectal adenocarcinoma progression and tumor-initiating cell frequency.
[ADAM17 knockdown increases sensitivity of SW480 cells to cetuximad].
Communicable Diseases
Plasma Ang2 and ADAM17 levels are elevated during clinical malaria; Ang2 level correlates with severity and expression of EPCR-binding PfEMP1.
Connective Tissue Diseases
Association of ADAM17 Expression Levels in Patients with Interstitial Lung Disease.
Corneal Injuries
ADAM17 Inhibitors Attenuate Corneal Epithelial Detachment Induced by Mustard Exposure.
Coronavirus Infections
A model for COVID-19-induced dysregulation of ACE2 shedding by ADAM17.
COVID-19
ACE2/ADAM17/TMPRSS2 Interplay May Be the Main Risk Factor for COVID-19.
ADAM17 inhibition may exert a protective effect on COVID-19.
Alpha-1-antitrypsin: A possible host protective factor against Covid-19.
Assessing COVID-19 susceptibility through analysis of the genetic and epigenetic diversity of ACE2-mediated SARS-CoV-2 entry.
Can Host Cell Proteins Like ACE2, ADAM17, TMPRSS2, Androgen Receptor be the Efficient Targets in SARS-CoV-2 Infection?
Ephrin-A1 and the sheddase ADAM12 are upregulated in COVID-19.
Hypothesis: Alpha-1-antitrypsin is a promising treatment option for COVID-19.
Identification of Novel MicroRNAs as Promising Therapeutics for SARS-CoV-2 by Regulating the EGFR-ADAM17 Axis: An In Silico Analysis.
Instigators of COVID-19 in Immune Cells are Increased in Tobacco Cigarette Smokers and Electronic Cigarette Vapers Compared to Non-smokers.
More light on cancer and COVID-19 reciprocal interaction.
Potential interactions of SARS-CoV-2 with human cell receptors in the skin: understanding the enigma for a lower frequency of skin lesions compared to other tissues.
Pulmonary, cardiac and renal distribution of ACE2, furin, TMPRSS2 and ADAM17 in rats with heart failure: Potential implication for COVID-19 disease.
Severe COVID-19 Patients Show an Increase in Soluble TNFR1 and ADAM17, with a Relationship to Mortality.
Sex differences in COVID-19: candidate pathways, genetics of ACE2, and sex hormones.
Shedding Light on COVID-19: ADAM17 the Missing Link?
Upregulation of the Renin-Angiotensin System Pathways and SARS-CoV-2 Infection: The Rationale for the Administration of Zinc-Chelating Agents in COVID-19 Patients.
Which ones, when and why should renin-angiotensin system inhibitors work against COVID-19?
Crohn Disease
Differential expression and regulation of ADAM17 and TIMP3 in acute inflamed intestinal epithelia.
Polymorphisms in the tumor necrosis factor/lipopolysaccharides pathway in Crohn disease in the Jewish Ashkenazi population.
Prediction of novel and selective TNF-alpha converting enzyme (TACE) inhibitors and characterization of correlative molecular descriptors by machine learning approaches.
Demyelinating Diseases
Oligodendrocyte Regeneration and CNS Remyelination Require TACE/ADAM17.
Tumor necrosis factor-alpha-converting enzyme is expressed in the inflamed peripheral nervous system.
Dermatitis
Does Adam17 cause the destruction of anchoring fibers via shedding tumor necrosis factor ? in bullous pemphigoid and dermatitis herpetiformis?
Epidermal ADAM17 maintains the skin barrier by regulating EGFR ligand-dependent terminal keratinocyte differentiation.
Dermatitis, Atopic
Notch activation by the metalloproteinase ADAM17 regulates myeloproliferation and atopic barrier immunity by suppressing epithelial cytokine synthesis.
Dermatomyositis
ADAM-17 is expressed in the inflammatory myopathy and is involved with interstitial lung disease.
The cell-specific expression of metalloproteinase-disintegrins (ADAMs) in inflammatory myopathies.
Diabetes Mellitus
Both Specific Endothelial and Proximal Tubular Adam17 Deletion Protect against Diabetic Nephropathy.
Diabetes Mellitus, Type 1
Both Specific Endothelial and Proximal Tubular Adam17 Deletion Protect against Diabetic Nephropathy.
Paricalcitol modulates ACE2 shedding and renal ADAM17 in NOD mice beyond proteinuria.
Diabetes Mellitus, Type 2
Impaired regulation of the TNF-alpha converting enzyme/tissue inhibitor of metalloproteinase 3 proteolytic system in skeletal muscle of obese type 2 diabetic patients: a new mechanism of insulin resistance in humans.
Implications of ADAM17 activation for hyperglycaemia, obesity and type 2 diabetes.
Increased Urinary Angiotensin Converting Enzyme 2 (ACE2) and Neprilysin (NEP) in Type 2 Diabetic Patients.
Plasminogen activator inhibitor 1 is an intracellular inhibitor of furin proprotein convertase.
TIMP3 is reduced in atherosclerotic plaques from subjects with type 2 diabetes and increased by SirT1.
Diabetic Nephropathies
Both Specific Endothelial and Proximal Tubular Adam17 Deletion Protect against Diabetic Nephropathy.
Bradykinin decreases podocyte permeability through ADAM17-dependent epidermal growth factor receptor activation and zonula occludens-1 rearrangement.
Daily exercise training protects against albuminuria and angiotensin converting enzyme 2 shedding in db/db diabetic mice.
HB-EGF release mediates glucose-induced activation of the epidermal growth factor receptor in mesangial cells.
High Glucose Up-regulates ADAM17 through HIF-1? in Mesangial Cells.
Loss of TIMP3 underlies diabetic nephropathy via FoxO1/STAT1 interplay.
Regulation of profibrotic responses by ADAM17 activation in high glucose requires its C-terminus and FAK.
Diabetic Retinopathy
Evaluation of Proteoforms of the Transmembrane Chemokines CXCL16 and CX3CL1, Their Receptors, and Their Processing Metalloproteinases ADAM10 and ADAM17 in Proliferative Diabetic Retinopathy.
Role of Endothelial ADAM17 in Early Vascular Changes Associated with Diabetic Retinopathy.
Down Syndrome
Reduced neuronal co-localisation of nardilysin and the putative alpha-secretases ADAM10 and ADAM17 in Alzheimer's disease and Down syndrome brains.
Encephalomyelitis
ADAM-17 and TIMP3 protein and mRNA expression in spinal cord white matter of rats with acute experimental autoimmune encephalomyelitis.
Encephalomyelitis, Autoimmune, Experimental
ADAM-17 and TIMP3 protein and mRNA expression in spinal cord white matter of rats with acute experimental autoimmune encephalomyelitis.
Endocrine Gland Neoplasms
Expression of tumor necrosis factor alpha converting enzyme in endocrine cancers.
Endotoxemia
ADAM17 controls IL-6 signaling by cleavage of the murine IL-6R? from the cell surface of leukocytes during inflammatory responses.
Construction of a lentiviral vector containing shRNA targeting ADAM17 and its role in attenuating endotoxemia in mice.
Shedding of the MER tyrosine kinase receptor is mediated by ADAM17 through a pathway involving reactive oxygen species, protein kinase {delta}, and P38 map kinase.
[Corrigendum] Construction of a lentiviral vector containing shRNA targeting ADAM17 and its role in attenuating endotoxemia in mice.
Epiretinal Membrane
Evaluation of Proteoforms of the Transmembrane Chemokines CXCL16 and CX3CL1, Their Receptors, and Their Processing Metalloproteinases ADAM10 and ADAM17 in Proliferative Diabetic Retinopathy.
Esophageal Squamous Cell Carcinoma
A disintegrin and metalloproteinase 17 mRNA and protein expression in esophageal squamous cell carcinoma, as well as its clinicopathological factors and prognosis.
ADAM17 and NF-?B p65 form a positive feedback loop that facilitates human esophageal squamous cell carcinoma cell viability.
Expression and clinical significance of ADAM17 protein in esophageal squamous cell carcinoma.
[Clinicopathological and prognostic significance of the expression of ADAM17 mRNA and protein in esophageal squamous cell carcinoma].
Esophagitis
IL-1{beta} and ADAM17 are central regulators of {beta}-defensin expression in Candida esophagitis.
Fatty Liver
Hepatocyte specific TIMP3 expression prevents diet dependent fatty liver disease and hepatocellular carcinoma.
Fibrosarcoma
Deletions in the cytoplasmic domain of iRhom1 and iRhom2 promote shedding of the TNF receptor by the protease ADAM17.
Gastrointestinal Stromal Tumors
Up-regulated expression of ADAM17 in gastrointestinal stromal tumors: coexpression with EGFR and EGFR ligands.
Glioblastoma
ADAM17 promotes U87 glioblastoma stem cell migration and invasion.
ADAM17 regulates self-renewal and differentiation of U87 glioblastoma stem cells.
Gene expression analysis of an EGFR indirectly related pathway identified PTEN and MMP9 as reliable diagnostic markers for human glial tumor specimens.
Metalloproteinases ADAM10 and ADAM17 Mediate Migration and Differentiation in Glioblastoma Sphere-Forming Cells.
PDIA6 regulation of ADAM17 shedding activity and EGFR-mediated migration and invasion of glioblastoma cells.
Glioma
ADAM17 promotes breast cancer cell malignant phenotype through EGFR-PI3K-AKT activation.
ADAM17 promotes glioma cell malignant phenotype.
ADAM17 promotes U87 glioblastoma stem cell migration and invasion.
ADAM17 regulates self-renewal and differentiation of U87 glioblastoma stem cells.
Diagnostic and prognostic value of a disintegrin and metalloproteinase-17 in patients with gliomas.
Dihydroartemisinin suppresses glioma proliferation and invasion via inhibition of the ADAM17 pathway.
Effects of tetrandrine on glioma cell malignant phenotype via inhibition of ADAM17.
FoxM1 drives ADAM17/EGFR activation loop to promote mesenchymal transition in glioblastoma.
Inhibition of ADAM17 reduces hypoxia-induced brain tumor cell invasiveness.
MiR-145 reduces ADAM17 expression and inhibits in vitro migration and invasion of glioma cells.
Overexpression of miR?145 in U87 cells reduces glioma cell malignant phenotype and promotes survival after in vivo implantation.
Sensitization of cerebral tissue in nude mice with photodynamic therapy induces ADAM17/TACE and promotes glioma cell invasion.
TGF-?1 promotes motility and invasiveness of glioma cells through activation of ADAM17.
The correlation between the expression of ADAM17, EGFR and Ki-67 in malignant gliomas.
Transcription factor Sp1 induces ADAM17 and contributes to tumor cell invasiveness under hypoxia.
Gliosarcoma
Inhibition of ADAM17 reduces hypoxia-induced brain tumor cell invasiveness.
Glomerulosclerosis, Focal Segmental
ADAM17 upregulation in human renal disease: a role in modulating TGF-alpha availability?
Gram-Negative Bacterial Infections
In vivo role of leukocyte ADAM17 in the inflammatory and host responses during E. coli-mediated peritonitis.
Graves Disease
Nuclear targeting of IGF-1 receptor in orbital fibroblasts from Graves' disease: apparent role of ADAM17.
Head and Neck Neoplasms
The soluble alpha chain of interleukin-15 receptor: a proinflammatory molecule associated with tumor progression in head and neck cancer.
Head Injuries, Closed
Distinct roles for metalloproteinases during traumatic brain injury.
Heart Diseases
ADAM-17: the enzyme that does it all.
Heart Failure
Increased expression of tumor necrosis factor-alpha converting enzyme and tumor necrosis factor-alpha in peripheral blood mononuclear cells in patients with advanced congestive heart failure.
Pulmonary, cardiac and renal distribution of ACE2, furin, TMPRSS2 and ADAM17 in rats with heart failure: Potential implication for COVID-19 disease.
Hepatitis
Ectodomain shedding of EGFR ligands and TNFR1 dictates hepatocyte apoptosis during fulminant hepatitis in mice.
Hepatitis, Alcoholic
Iron-Overload triggers ADAM-17 mediated inflammation in Severe Alcoholic Hepatitis.
HIV Infections
HIV Nef- and Notch1-dependent Endocytosis of ADAM17 Induces Vesicular TNF Secretion in Chronic HIV Infection.
Hyperglycemia
ADAM17 mediates Nox4 expression and NADPH oxidase activity in the kidney cortex of OVE26 mice.
Rosiglitazone treatment of type 2 diabetic db/db mice attenuates urinary albumin and angiotensin converting enzyme 2 excretion.
Hyperparathyroidism, Primary
ADAM17, a New Player in the Pathogenesis of Chronic Kidney Disease-Mineral and Bone Disorder.
Hyperparathyroidism, Secondary
Contribution of phosphorus and PTH to the development of cardiac hypertrophy and fibrosis in an experimental model of chronic renal failure.
Hypersensitivity
Impaired mechanical, heat, and cold nociception in a murine model of genetic TACE/ADAM17 knockdown.
Hypertension
?-Lipoic acid reduces neurogenic hypertension by blunting oxidative stress-mediated increase in ADAM17.
ACE2 and ADAM17 Interaction Regulates the Activity of Presympathetic Neurons.
Activation of ADAM17 (A Disintegrin and Metalloprotease 17) on Glutamatergic Neurons Selectively Promotes Sympathoexcitation.
ADAM17-Mediated Shedding of Inflammatory Cytokines in Hypertension.
Brain ACE2 Shedding Contributes to the Development of Neurogenic Hypertension.
Cilostazol inhibits interleukin-1-induced ADAM17 expression through cAMP independent signaling in vascular smooth muscle cells.
Clinical Relevance and Role of Neuronal AT1 Receptors in ADAM17-Mediated ACE2 Shedding in Neurogenic Hypertension.
Loss of smooth muscle cell disintegrin and metalloproteinase 17 transiently suppresses angiotensin II-induced hypertension and end-organ damage.
Lung ACE2 and ADAM17 in pulmonary arterial hypertension: Implications for COVID-19?
Role of ADAM17 in kidney disease.
Role of epidermal growth factor receptor and endoplasmic reticulum stress in vascular remodeling induced by angiotensin II.
The compensatory renin-angiotensin system in the central regulation of arterial pressure: new avenues and new challenges.
The Role of iRhom2 in Metabolic and Cardiovascular-Related Disorders.
TRPC3 channel confers cerebrovascular remodelling during hypertension via transactivation of EGF receptor signalling.
Vascular ADAM17 as a Novel Therapeutic Target in Mediating Cardiovascular Hypertrophy and Perivascular Fibrosis Induced by Angiotensin II.
Vascular Induction of a Disintegrin and Metalloprotease 17 by Angiotensin II Through Hypoxia Inducible Factor 1?
Which ones, when and why should renin-angiotensin system inhibitors work against COVID-19?
Hypopharyngeal Neoplasms
MiR-338-3p inhibits cell migration and invasion in human hypopharyngeal cancer via downregulation of ADAM17.
Hypothalamic Neoplasms
Hypothalamic tumor necrosis factor-alpha converting enzyme mediates excitatory amino acid-dependent neuron-to-glia signaling in the neuroendocrine brain.
Idiopathic Pulmonary Fibrosis
Association of ADAM17 Expression Levels in Patients with Interstitial Lung Disease.
Infarction, Middle Cerebral Artery
In vitro ischemic tolerance involves upregulation of glutamate transport partly mediated by the TACE/ADAM17-tumor necrosis factor-alpha pathway.
Infections
ADAM17 activation in circulating neutrophils following bacterial challenge impairs their recruitment.
ADAM17 controls IL-6 signaling by cleavage of the murine IL-6R? from the cell surface of leukocytes during inflammatory responses.
ADAM17 silencing by adenovirus encoding miRNA-embedded siRNA revealed essential signal transduction by angiotensin II in vascular smooth muscle cells.
Analysis of cell hyperplasia and parietal cell dysfunction induced by Ostertagia ostertagi infection.
ATP-mediated transactivation of the epidermal growth factor receptor in airway epithelial cells involves DUOX1-dependent oxidation of Src and ADAM17.
Decoding the enigma of antiviral crisis: Does one target molecule regulate all?
Ectodomain Shedding by ADAM17: Its Role in Neutrophil Recruitment and the Impairment of This Process during Sepsis.
Ehrlichia chaffeensis TRP120 Activates Canonical Notch Signaling To Downregulate TLR2/4 Expression and Promote Intracellular Survival.
Expression Analyses of MicroRNAs in Hamster Lung Tissues Infected by SARS-CoV-2.
Expression levels of A disintegrin and metalloproteases (ADAMs), and Th17-related cytokines and their association with Helicobacter pylori infection in patients with gastroduodenal diseases.
Helicobacter pylori CagL Activates ADAM17 to Induce Repression of the Gastric H, K-ATPase alpha Subunit.
Instigators of COVID-19 in Immune Cells are Increased in Tobacco Cigarette Smokers and Electronic Cigarette Vapers Compared to Non-smokers.
Metalloprotease ADAM17 regulates porcine epidemic diarrhea virus infection by modifying aminopeptidase N.
Modulation of CD163 expression by metalloprotease ADAM17 regulates porcine reproductive and respiratory syndrome virus entry.
MUC1 limits Helicobacter pylori infection both by steric hindrance and by acting as a releasable decoy.
Plasma Ang2 and ADAM17 levels are elevated during clinical malaria; Ang2 level correlates with severity and expression of EPCR-binding PfEMP1.
Regulation of A disintegrin and metalloproteinase (ADAM) family sheddases ADAM10 and ADAM17: The emerging role of tetraspanins and rhomboids.
Shed GP of Ebola virus triggers immune activation and increased vascular permeability.
Shedding Light on COVID-19: ADAM17 the Missing Link?
Shedding of TNF receptor 2 by effector CD8? T cells by ADAM17 is important for regulating TNF-? availability during influenza infection.
Tetraspanin CD9 affects HPV16 infection by modulating ADAM17 activity and the ERK signalling pathway.
TREM2 suppresses the proinflammatory response to facilitate PRRSV infection via PI3K/NF-?B signaling.
Inflammatory Bowel Diseases
Inflammatory bowel disease and ADAM17 deletion.
Influenza, Human
Shedding of TNF receptor 2 by effector CD8? T cells by ADAM17 is important for regulating TNF-? availability during influenza infection.
Insulin Resistance
ADAM17_i33708A>G polymorphism interacts with dietary n-6 polyunsaturated fatty acids to modulate obesity risk in the Genetics of Lipid Lowering Drugs and Diet Network study.
Discriminatory metabolic and inflammatory parameters in serum and omental adipose tissue of obese patients with different insulin sensitivity.
Increased tumor necrosis factor alpha-converting enzyme activity induces insulin resistance and hepatosteatosis in mice.
Mice heterozygous for tumor necrosis factor-alpha converting enzyme are protected from obesity-induced insulin resistance and diabetes.
The role of ADAM17 in metabolic inflammation.
WITHDRAWN: Adipocyte Deletion of ADAM17 Leads to Insulin Resistance in Association with Age and HFD in Mice.
[The two sides of ADAM17 in inflammation: implications in atherosclerosis and obesity]
Intestinal Neoplasms
ADAM17 is required for EGF-R-induced intestinal tumors via IL-6 trans-signaling.
Functional Characterization of Colon Cancer-Associated Mutations in ADAM17: Modifications in the Pro-Domain Interfere with Trafficking and Maturation.
Intestinal Volvulus
Human colonic myocytes are involved in postischemic inflammation through ADAM17-dependent TNFalpha production.
Iron Overload
The Effect of TCM-Induced HAMP on Key Enzymes in the Hydrolysis of AD Model Cells.
Ischemic Stroke
Association between ADAM17 Promoter Polymorphisms and Ischemic Stroke in a Chinese Population.
Changes in platelet GPIb? and ADAM17 during the acute stage of atherosclerotic ischemic stroke among Chinese.
Joint Diseases
Lack of tissue inhibitor of metalloproteinases-3 results in an enhanced inflammatory response in antigen-induced arthritis.
Novel functions of inactive rhomboid proteins in immunity and disease.
Keloid
Multi-Antigen Imaging Reveals Inflammatory DC, ADAM17 and Neprilysin as Effectors in Keloid Formation.
Keratoderma, Palmoplantar, Diffuse
Insights into desmosome biology from inherited human skin disease and cardiocutaneous syndromes.
Kidney Diseases
CXCL16 Is Expressed in Podocytes and Acts as a Scavenger Receptor for Oxidized Low-Density Lipoprotein.
Role of ADAM17 in kidney disease.
The induction of C/EBP? contributes to vitamin D inhibition of ADAM17 expression and parathyroid hyperplasia in kidney disease.
Kidney Diseases, Cystic
ADAM17 promotes proliferation of collecting duct kidney epithelial cells through ERK activation and increased glycolysis in polycystic kidney disease.
Kidney Failure, Chronic
Association of CD30 transcripts with Th1 responses and proinflammatory cytokines in patients with end-stage renal disease.
Kidney Neoplasms
Human renal cancer cells express a novel membrane-bound interleukin-15 that induces, in response to the soluble interleukin-15 receptor alpha chain, epithelial-to-mesenchymal transition.
MicroRNA-145 Targets the Metalloprotease ADAM17 and Is Suppressed in Renal Cell Carcinoma Patients.
Klatskin Tumor
ADAM-17 is a poor prognostic indicator for patients with hilar cholangiocarcinoma and is regulated by FoxM1.
Leukemia
High molecular weight hyaluronic acid down-regulates the gene expression of osteoarthritis-associated cytokines and enzymes in fibroblast-like synoviocytes from patients with early osteoarthritis.
Hydroquinone-induced miR-122 down-regulation elicits ADAM17 up-regulation, leading to increased soluble TNF-? production in human leukemia cells with expressed Bcr/Abl.
Modulation of autocrine TNF-alpha-stimulated matrix metalloproteinase 9 (MMP-9) expression by mitogen-activated protein kinases in THP-1 monocytic cells.
Selective use of ADAM10 and ADAM17 in activation of Notch1 signaling.
Suppression of Akt/Foxp3-mediated miR-183 expression blocks Sp1-mediated ADAM17 expression and TNF?-mediated NF?B activation in piceatannol-treated human leukemia U937 cells.
Taiwan cobra phospholipase A2 suppresses ERK-mediated ADAM17 maturation, thus reducing secreted TNF-? production in human leukemia U937 cells.
Leukemia, Myeloid, Acute
Targeting natural killer cells to acute myeloid leukemia in vitro with a CD16 x 33 bispecific killer cell engager and ADAM17 inhibition.
Listeriosis
The role of ADAM17 in the T-cell response against bacterial pathogens.
Liver Cirrhosis
ADAM10 and ADAM17 regulate EGFR, c-Met and TNF RI signalling in liver regeneration and fibrosis.
ADAM17 mRNA expression and pathological features of hepatocellular carcinoma.
CX3CL1/FRACTALKINE SHEDDING BY HUMAN HEPATIC STELLATE CELLS: CONTRIBUTION TO CHRONIC INFLAMMATION IN THE LIVER.
iRhom2 inhibits bile duct obstruction-induced liver fibrosis.
Liver Diseases
CX3CL1/FRACTALKINE SHEDDING BY HUMAN HEPATIC STELLATE CELLS: CONTRIBUTION TO CHRONIC INFLAMMATION IN THE LIVER.
Liver Failure
Ectodomain shedding of EGFR ligands and TNFR1 dictates hepatocyte apoptosis during fulminant hepatitis in mice.
Liver Neoplasms
iNOS promotes CD24+CD133+ liver cancer stem cell phenotype through a TACE/ADAM17-dependent Notch signaling pathway.
MicroRNA-145 inhibits cell proliferation by directly targeting ADAM17 in hepatocellular carcinoma.
Role of ADAM17 in invasion and migration of CD133-expressing liver cancer stem cells after irradiation.
Lung Diseases
Instigators of COVID-19 in Immune Cells are Increased in Tobacco Cigarette Smokers and Electronic Cigarette Vapers Compared to Non-smokers.
The Role of CX3CL1 and ADAM17 in Pathogenesis of Diffuse Parenchymal Lung Diseases.
Lung Diseases, Interstitial
ADAM-17 is expressed in the inflammatory myopathy and is involved with interstitial lung disease.
Association of ADAM17 Expression Levels in Patients with Interstitial Lung Disease.
Correction to: ADAM-17 is expressed in the inflammatory myopathy and is involved with interstitial lung disease.
The Role of CX3CL1 and ADAM17 in Pathogenesis of Diffuse Parenchymal Lung Diseases.
Lung Injury
Neuregulin-1-human epidermal receptor-2 signaling is a central regulator of pulmonary epithelial permeability and acute lung injury.
Nonischemic lung injury by mediators from unilateral ischemic reperfused lung: ameliorating effect of tumor necrosis factor-alpha-converting enzyme inhibitor.
Lung Neoplasms
A novel bispecific single-chain antibody for ADAM17 and CD3 induces T-cell-mediated lysis of prostate cancer cells.
ADAM17 is overexpressed in non-small cell lung cancer and its expression correlates with poor patient survival.
ADAM17 regulates epidermal growth factor receptor expression through the activation of Notch1 in non-small cell lung cancer.
ADAM17 selectively activates the IL-6 trans-signaling/ERK MAPK axis in KRAS-addicted lung cancer.
ADAM17 silencing suppresses the migration and invasion of non-small cell lung cancer.
ADAM17: An Emerging Therapeutic Target for Lung Cancer.
Estrogen upregulates MICA/B expression in human non-small cell lung cancer through the regulation of ADAM17.
Identification of five candidate lung cancer biomarkers by proteomic analysis of conditioned media of four lung cancer cell lines.
Lung cancer-derived galectin-1 enhances tumorigenic potentiation of tumor associated dendritic cells by expressing HB-EGF.
Novel ADAM-17 inhibitor ZLDI-8 inhibits the proliferation and metastasis of chemo-resistant non-small-cell lung cancer by reversing Notch and epithelial mesenchymal transition in vitro and in vivo.
Platelet-mediated shedding of NKG2D ligands impairs NK cell immune-surveillance of tumor cells.
Savior or not: ADAM17 inhibitors overcome radiotherapy-resistance in non-small cell lung cancer.
Secretome Signature Identifies ADAM17 as Novel Target for Radiosensitization of Non-Small Cell Lung Cancer.
Sema4D expression and secretion are increased by HIF-1? and inhibit osteogenesis in bone metastases of lung cancer.
Lupus Nephritis
Novel functions of inactive rhomboid proteins in immunity and disease.
Lymphatic Metastasis
A disintegrin and metalloproteinase 17 mRNA and protein expression in esophageal squamous cell carcinoma, as well as its clinicopathological factors and prognosis.
ADAM-17 expression in breast cancer correlates with variables of tumor progression.
ADAM-17 predicts adverse outcome in patients with breast cancer.
ADAM17 is associated with EMMPRIN and predicts poor prognosis in patients with uterine cervical carcinoma.
ADAM17 is overexpressed in non-small cell lung cancer and its expression correlates with poor patient survival.
ADAM17 promotes lymph node metastasis in gastric cancer via activation of the Notch and Wnt signaling pathways.
Expression and clinical significance of ADAM17 protein in esophageal squamous cell carcinoma.
Prognostic significance of ADAM17 expression in patients with gastric cancer who underwent curative gastrectomy.
Prognostic Significance of ADAM17 for Gastric Cancer Survival: A Meta-Analysis.
Prognostic value of ADAM17 in human gastric cancer.
Macular Degeneration
ADAM17 mediates ectodomain shedding of the soluble VLDL receptor fragment in the retinal epithelium.
Malaria
Plasma Ang2 and ADAM17 levels are elevated during clinical malaria; Ang2 level correlates with severity and expression of EPCR-binding PfEMP1.
Massive Hepatic Necrosis
Ectodomain shedding of EGFR ligands and TNFR1 dictates hepatocyte apoptosis during fulminant hepatitis in mice.
Melanoma
ADAM10 is the constitutive functional sheddase of CD44 in human melanoma cells.
Molecular Profiling of ADAM12 and ADAM17 Genes in Human Malignant Melanoma.
Rosmarinic acid inhibits proliferation and migration, promotes apoptosis and enhances cisplatin sensitivity of melanoma cells through inhibiting ADAM17/EGFR/AKT/GSK3? axis.
Shedding light on proteolytic cleavage of CD44: the responsible sheddase and functional significance of shedding.
UV-induced EGFR signal transactivation is dependent on proligand shedding by activated metalloproteases in skin cancer cell lines.
Meningitis
Adjuvant TACE inhibitor treatment improves the outcome of TLR2-/- mice with experimental pneumococcal meningitis.
Current concepts in the pathogenesis of meningitis caused by Streptococcus pneumoniae.
Meningitis, Bacterial
Doxycycline reduces mortality and injury to the brain and cochlea in experimental pneumococcal meningitis.
In pneumococcal meningitis a novel water-soluble inhibitor of matrix metalloproteinases and TNF-alpha converting enzyme attenuates seizures and injury of the cerebral cortex.
Meningitis, Pneumococcal
In pneumococcal meningitis a novel water-soluble inhibitor of matrix metalloproteinases and TNF-alpha converting enzyme attenuates seizures and injury of the cerebral cortex.
Metabolic Syndrome
Implications of ADAM17 activation for hyperglycaemia, obesity and type 2 diabetes.
Plasminogen activator inhibitor 1 is an intracellular inhibitor of furin proprotein convertase.
Mouth Neoplasms
ADAM17-mediated CD44 cleavage promotes orasphere formation or stemness and tumorigenesis in HNSCC.
Mucocutaneous Lymph Node Syndrome
Genetic variants of ADAM17 are implicated in the pathological process of Kawasaki disease and secondary coronary artery lesions via the TGF-?/SMAD3 signaling pathway.
Multiple Sclerosis
Expression of ADAM-17, TIMP-3 and fractalkine in the human adult brain endothelial cell line, hCMEC/D3, following pro-inflammatory cytokine treatment.
TNF-alpha converting enzyme (TACE) protein expression in different clinical subtypes of multiple sclerosis.
Upregulation of ADAM-17 expression in active lesions in multiple sclerosis.
Myocardial Infarction
Cardiomyocyte A Disintegrin And Metalloproteinase 17 (ADAM17) Is Essential in Post-Myocardial Infarction Repair by Regulating Angiogenesis.
Effect of miR-26a-5p targeting ADAM17 gene on apoptosis, inflammatory factors and oxidative stress response of myocardial cells in hypoxic model.
Enhanced ADAM17 expression is associated with cardiac remodeling in rats with acute myocardial infarction.
MiR-708-3p Alleviates Inflammation and Myocardial Injury After Myocardial Infarction by Suppressing ADAM17 Expression.
Syzygium Polyanthum Reduced TNF-? and ADAM17 Protein Expression in Myocardial Infarction Rat Model.
The expression of TNF-alpha converting enzyme at the site of ruptured plaques in patients with acute myocardial infarction.
Myocarditis
Expression of tumor necrosis factor-alpha--converting enzyme and tumor necrosis factor-alpha in human myocarditis.
Myositis
ADAM-17 is expressed in the inflammatory myopathy and is involved with interstitial lung disease.
Correction to: ADAM-17 is expressed in the inflammatory myopathy and is involved with interstitial lung disease.
The cell-specific expression of metalloproteinase-disintegrins (ADAMs) in inflammatory myopathies.
Myositis, Inclusion Body
The cell-specific expression of metalloproteinase-disintegrins (ADAMs) in inflammatory myopathies.
Nasal Polyps
Expression of ADAM17 and ADAM10 in nasal polyps.
Nasopharyngeal Carcinoma
MiR-145, a microRNA targeting ADAM17, inhibits the invasion and migration of nasopharyngeal carcinoma cells.
Neoplasm Metastasis
A disintegrin and metalloproteinase 17 mRNA and protein expression in esophageal squamous cell carcinoma, as well as its clinicopathological factors and prognosis.
A transmembrane C-terminal fragment of syndecan-1 is generated by the metalloproteinase ADAM17 and promotes lung epithelial tumor cell migration and lung metastasis formation.
A-Disintegrin and Metalloproteinase (ADAM) 17 Enzymatically Degrades Interferon-gamma.
ADAM-17 associated with CD44 cleavage and metastasis in oral squamous cell carcinoma.
ADAM-17 expression in breast cancer correlates with variables of tumor progression.
ADAM-17 predicts adverse outcome in patients with breast cancer.
ADAM17 is associated with EMMPRIN and predicts poor prognosis in patients with uterine cervical carcinoma.
ADAM17 is overexpressed in non-small cell lung cancer and its expression correlates with poor patient survival.
ADAM17 promotes cell migration and invasion through the integrin ?1 pathway in hepatocellular carcinoma.
ADAM17 promotes lymph node metastasis in gastric cancer via activation of the Notch and Wnt signaling pathways.
ADAM17 promotes the invasion of hepatocellular carcinoma via upregulation MMP21.
ADAM17 targets MMP-2 and MMP-9 via EGFR-MEK-ERK pathway activation to promote prostate cancer cell invasion.
Expression and clinical significance of ADAM17 protein in esophageal squamous cell carcinoma.
Expression of Migration-Related Genes in Human Colorectal Cancer and Activity of a Disintegrin and Metalloproteinase 17.
Mass spectrometry-based proteomics revealed Glypican-1 as a novel ADAM17 substrate.
MicroRNA-122, a tumor suppressor microRNA that regulates intrahepatic metastasis of hepatocellular carcinoma.
Novel ADAM-17 inhibitor ZLDI-8 inhibits the metastasis of hepatocellular carcinoma by reversing epithelial-mesenchymal transition in vitro and in vivo.
Novel ADAM-17 inhibitor ZLDI-8 inhibits the proliferation and metastasis of chemo-resistant non-small-cell lung cancer by reversing Notch and epithelial mesenchymal transition in vitro and in vivo.
Nox1 promotes colon cancer cell metastasis via activation of the ADAM17 pathway.
Prognostic significance of ADAM17 expression in patients with gastric cancer who underwent curative gastrectomy.
Prognostic Significance of ADAM17 for Gastric Cancer Survival: A Meta-Analysis.
Prognostic value of ADAM17 in human gastric cancer.
Regulation of Platelet-Derived ADAM17: A Biomarker Approach for Breast Cancer?
Sema4D expression and secretion are increased by HIF-1? and inhibit osteogenesis in bone metastases of lung cancer.
The role of microRNA in metastatic colorectal cancer and its significance in cancer prognosis and treatment.
Therapeutic potential of ADAM17 modulation in gastric cancer through regulation of the EGFR and TNF-? signalling pathways.
Upregulated Expression of ADAM17 Is a Prognostic Marker for Patients With Gastric Cancer.
Neoplasms
(E)-2(R)-[1(S)-(Hydroxycarbamoyl)-4-phenyl-3-butenyl]-2'-isobutyl-2'-(methanesulfonyl)-4-methylvalerohydrazide (Ro 32-7315), a selective and orally active inhibitor of tumor necrosis factor-alpha convertase.
15,16-dihydrotanshinone I suppresses the activation of BV-2 cell, a murine microglia cell line, by lipopolysaccharide.
2 angstrom X-ray structure of adamalysin II complexed with a peptide phosphonate inhibitor adopting a retro-binding mode.
3D-quantitative structure-activity relationship studies on benzothiadiazepine hydroxamates as inhibitors of tumor necrosis factor-alpha converting enzyme.
5-HT2A receptor induces ERK phosphorylation and proliferation through ADAM-17 tumor necrosis factor-alpha-converting enzyme (TACE) activation and heparin-bound epidermal growth factor-like growth factor (HB-EGF) shedding in mesangial cells.
A cellular metalloproteinase activates Vibrio cholerae pro-cytolysin.
A combinational approach to restore cytokine balance and to inhibit virus growth may promote patient recovery in severe COVID-19 cases.
A comparison of the binding sites of matrix metalloproteinases and tumor necrosis factor-alpha converting enzyme: implications for selectivity.
A continuous fluorimetric assay for tumor necrosis factor-alpha converting enzyme.
A disintegrin and metalloproteinase 17 (ADAM17) and epidermal growth factor receptor (EGFR) signaling drive the epithelial response to Staphylococcus aureus toxic shock syndrome toxin-1 (TSST-1).
A disintegrin and metalloproteinase 17 regulates TNF and TNFR1 levels in inflammation and liver regeneration in mice.
A Disintegrin and Metalloproteinase 9 (ADAM9) in Advanced Hepatocellular Carcinoma and Their Role as a Biomarker During Hepatocellular Carcinoma Immunotherapy.
A Disintegrin and Metalloproteinase Domain 17 Regulates Colorectal Cancer Stem Cells and Chemosensitivity Via Notch1 Signaling.
A disintegrin and metalloproteinase 17 mRNA and protein expression in esophageal squamous cell carcinoma, as well as its clinicopathological factors and prognosis.
A Genetically Engineered Primary Human Natural Killer Cell Platform for Cancer Immunotherapy.
A metal-based tumour necrosis factor-alpha converting enzyme inhibitor.
A Monoclonal Antibody to ADAM17 Inhibits Tumor Growth by Inhibiting EGFR and Non-EGFR-Mediated Pathways.
A novel bispecific single-chain antibody for ADAM17 and CD3 induces T-cell-mediated lysis of prostate cancer cells.
A novel inhibitor of tumor necrosis factor-alpha converting enzyme ameliorates polycystic kidney disease.
A novel marker ADAM17 for clear cell renal cell carcinomas: Implication for patients' prognosis.
A soluble form of the Mer receptor tyrosine kinase inhibits macrophage clearance of apoptotic cells and platelet aggregation.
A transforming Src mutant increases the bioavailability of EGFR ligands via stimulation of the cell-surface metalloproteinase ADAM17.
A transmembrane C-terminal fragment of syndecan-1 is generated by the metalloproteinase ADAM17 and promotes lung epithelial tumor cell migration and lung metastasis formation.
A wake-like state in vitro induced by transmembrane TNF/soluble TNF receptor reverse signaling.
A-Disintegrin and Metalloproteinase (ADAM) 17 Enzymatically Degrades Interferon-gamma.
Abrogation of tumor necrosis factor-alpha converting enzyme inhibits embryonic lung morphogenesis in culture.
Activation of ADAM17 by IL-15 Limits Human NK Cell Proliferation.
Activation of endothelial intrinsic NF-{kappa}B pathway impairs protein C anticoagulation mechanism and promotes coagulation in endotoxemic mice.
Activation of epidermal growth factor receptor signaling by the prostaglandin E(2) receptor EP4 pathway during gastric tumorigenesis.
Activation of tumor necrosis factor-alpha-converting enzyme-mediated ectodomain shedding by nitric oxide.
ADAM 17 and Epithelial-to-Mesenchymal Transition: The Evolving Story and Its Link to Fibrosis and Cancer.
ADAM metallopeptidase domain 17 (ADAM17) is naturally processed through major histocompatibility complex (MHC) class I molecules and is a potential immunotherapeutic target in breast, ovarian and prostate cancers.
ADAM proteases: Emerging role and targeting of the non-catalytic domains.
ADAM-17 associated with CD44 cleavage and metastasis in oral squamous cell carcinoma.
ADAM-17 expression in breast cancer correlates with variables of tumor progression.
ADAM-17 expression is enhanced by FoxM1 and is a poor prognostic sign in gastric carcinoma.
ADAM-17 is a poor prognostic indicator for patients with hilar cholangiocarcinoma and is regulated by FoxM1.
ADAM-17 is expressed in the inflammatory myopathy and is involved with interstitial lung disease.
ADAM-17 over-expression in gallbladder carcinoma correlates with poor prognosis of patients.
ADAM-17 predicts adverse outcome in patients with breast cancer.
ADAM-17-independent shedding of L-selectin.
ADAM-17: a novel therapeutic target for triple negative breast cancer.
ADAM-17: the enzyme that does it all.
ADAM10 and ADAM17 cleave PD-L1 to mediate PD-(L)1 inhibitor resistance.
ADAM10 correlates with uveal melanoma metastasis and promotes in vitro invasion.
ADAM10 is the constitutive functional sheddase of CD44 in human melanoma cells.
ADAM10 new selective inhibitors reduce NKG2D ligand release sensitizing Hodgkin lymphoma cells to NKG2D-mediated killing.
ADAM10 Sheddase Activity is a Potential Lung-Cancer Biomarker.
ADAM12 and ADAM17 Gene Expression in Laser-capture Microdissected and Non-microdissected Breast Tumors.
ADAM17 Activity and IL-6 Trans-Signaling in Inflammation and Cancer.
ADAM17 and NF-?B p65 form a positive feedback loop that facilitates human esophageal squamous cell carcinoma cell viability.
ADAM17 as a therapeutic target in multiple diseases.
ADAM17 at the interface between inflammation and autoimmunity.
ADAM17 but not ADAM10 mediates tumor necrosis factor-alpha and L-selectin shedding from leukocyte membranes.
ADAM17 controls endochondral ossification by regulating terminal differentiation of chondrocytes.
ADAM17 deficiency by mature neutrophils has differential effects on L-selectin shedding.
ADAM17 in tumor associated leukocytes regulates inflammatory mediators and promotes mammary tumor formation.
ADAM17 inhibition enhances platinum efficiency in ovarian cancer.
ADAM17 Inhibition Increases the Impact of Cisplatin Treatment in Ovarian Cancer Spheroids.
ADAM17 is a survival factor for microglial cells in vitro and in vivo after spinal cord injury in mice.
ADAM17 is a tumor promoter and therapeutic target in Western diet-associated colon cancer.
ADAM17 is associated with EMMPRIN and predicts poor prognosis in patients with uterine cervical carcinoma.
ADAM17 is overexpressed in non-small cell lung cancer and its expression correlates with poor patient survival.
ADAM17 is required for EGF-R-induced intestinal tumors via IL-6 trans-signaling.
ADAM17 mediates hypoxia-induced drug resistance in hepatocellular carcinoma cells through activation of EGFR/PI3K/Akt pathway.
ADAM17 mRNA expression and pathological features of hepatocellular carcinoma.
ADAM17 promotes cell migration and invasion through the integrin ?1 pathway in hepatocellular carcinoma.
ADAM17 promotes epithelial-mesenchymal transition via TGF-?/Smad pathway in gastric carcinoma cells.
ADAM17 promotes glioma cell malignant phenotype.
ADAM17 Promotes Motility, Invasion, and Sprouting of Lymphatic Endothelial Cells.
ADAM17 promotes the invasion of hepatocellular carcinoma via upregulation MMP21.
ADAM17 regulates prostate cancer cell proliferation through mediating cell cycle progression by EGFR/PI3K/AKT pathway.
ADAM17 regulates TNF-? expression upon lipopolysaccharide stimulation in oral keratinocytes.
ADAM17 selectively activates the IL-6 trans-signaling/ERK MAPK axis in KRAS-addicted lung cancer.
ADAM17 silencing in mouse colon carcinoma cells: the effect on tumoricidal cytokines and angiogenesis.
ADAM17 silencing suppresses the migration and invasion of non-small cell lung cancer.
ADAM17 stabilizes its interacting partner inactive Rhomboid 2 (iRhom2) but not inactive Rhomboid 1 (iRhom1).
ADAM17 targets MMP-2 and MMP-9 via EGFR-MEK-ERK pathway activation to promote prostate cancer cell invasion.
ADAM17, a New Player in the Pathogenesis of Chronic Kidney Disease-Mineral and Bone Disorder.
ADAM17, shedding, TACE as therapeutic targets.
ADAM17-overexpressing breast cancer cells selectively targeted by antibody-toxin conjugates.
ADAM17-siRNA inhibits MCF-7 breast cancer through EGFR-PI3K-AKT activation.
ADAM17: a molecular switch to control inflammation and tissue regeneration.
ADAM17: An Emerging Therapeutic Target for Lung Cancer.
ADAM17_i33708A>G polymorphism interacts with dietary n-6 polyunsaturated fatty acids to modulate obesity risk in the Genetics of Lipid Lowering Drugs and Diet Network study.
ADAMs in cancer cell proliferation and progression.
Aldose reductase regulates high glucose-induced ectodomain shedding of tumor necrosis factor (TNF)-alpha via protein kinase C-delta and TNF-alpha converting enzyme in vascular smooth muscle cells.
Alpha,Beta-cyclic-beta-benzamido hydroxamic acids: Novel oxaspiro[4.4]nonane templates for the discovery of potent, selective, orally bioavailable inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).
An essential role for ectodomain shedding in mammalian development.
Angiotensin-converting enzyme 2 ectodomain shedding cleavage-site identification: determinants and constraints.
Anthranilate derivatives as TACE inhibitors: Docking based CoMFA and CoMSIA analyses.
Anti-ADAM17 monoclonal antibody MEDI3622 increases IFN? production by human NK cells in the presence of antibody-bound tumor cells.
Anti-inflammatory bioactivities of honokiol through inhibition of protein kinase C, mitogen-activated protein kinase, and the NF-kappaB pathway to reduce LPS-induced TNFalpha and NO expression.
Anti-tumour effects of a specific anti-ADAM17 antibody in an ovarian cancer model in vivo.
APP processing and the APP-KPI domain involvement in the amyloid cascade.
Application of structural dynamic approaches provide novel insights into the enzymatic mechanism of the tumor necrosis factor-alpha-converting enzyme.
Autophagy regulates cisplatin-induced stemness and chemoresistance via the upregulation of CD44, ABCB1 and ADAM17 in oral squamous cell carcinoma.
B cell ADAM17 controls T cell independent humoral immune responses through regulation of TACI and CD138.
Beta-aryl-succinic acid hydroxamates as dual inhibitors of matrix metalloproteinases and tumor necrosis factor alpha converting enzyme.
Biochemical and pharmacological criteria define two shedding activities for TRANCE/OPGL that are distinct from the tumor necrosis factor alpha convertase.
Bisphenol A disrupts Notch signaling by inhibiting gamma-secretase activity and causes eye dysplasia of Xenopus laevis.
Bisphenol-A and Nonylphenol Induce Apoptosis in Reproductive Tract Cancer Cell Lines by the Activation of ADAM17.
Blockade of tumor necrosis factor-alpha-converting enzyme improves experimental small intestinal damage by decreasing matrix metalloproteinase-3 production in rats.
Bone morphogenetic protein 15 and fibroblast growth factor 10 enhance cumulus expansion, glucose uptake, and expression of genes in the ovulatory cascade during in vitro maturation of bovine cumulus-oocyte complexes.
Breast tumor cell TACE-shed MCSF promotes pro-angiogenic macrophages through NF-?B signaling.
Brief Report: Requirement of TACE/ADAM17 for Hair Follicle Bulge Niche Establishment.
Cannabinoids induce cancer cell proliferation via tumor necrosis factor alpha-converting enzyme (TACE/ADAM17)-mediated transactivation of the epidermal growth factor receptor.
Caught in the act: observation of polymorphonuclear neutrophils for the regulation of tumor necrosis factor-alpha release by tumor necrosis factor-alpha converting enzyme in patients with secondary peritonitis.
Caveolae-Associated Protein 3 (Cavin-3) Influences Adipogenesis via TACE-Mediated Pref-1 Shedding.
cDNA cloning of mouse tumor necrosis factor-alpha converting enzyme (TACE) and partial analysis of its promoter.
Cell-cell interaction promotes rat marrow stromal cell differentiation into endothelial cell via activation of TACE/TNF-alpha signaling.
Cell-matrix interaction via CD44 is independently regulated by different metalloproteinases activated in response to extracellular Ca(2+) influx and PKC activation.
Cellular prion protein coupling to TACE-dependent TNF-alpha shedding controls neurotransmitter catabolism in neuronal cells.
Changes in expressions of ADAM9, 10, and 17 as well as ?-secretase activity in renal cell carcinoma.
Characterization of (2R, 3S)-2-([[4-(2-butynyloxy)phenyl]sulfonyl]amino)-N,3-dihydroxybutanamide, a potent and selective inhibitor of TNF-alpha converting enzyme.
Characterization of growth factor-induced serine phosphorylation of tumor necrosis factor-alpha converting enzyme and of an alternatively translated polypeptide.
Characterization of the tumour necrosis factor alpha-converting enzyme, TACE/ADAM17.
Chemotherapy-induced activation of ADAM-17: a novel mechanism of drug resistance in colorectal cancer.
Chlorella powder inhibits the activities of peptidase cathepsin S, PLA2, cyclooxygenase-2, thromboxane synthase, tyrosine phosphatases, tumor necrosis factor-alpha converting enzyme, calpain and kinases.
Cigarette smoke induces MUC5AC mucin overproduction via tumor necrosis factor-alpha-converting enzyme in human airway epithelial (NCI-H292) cells.
Clinical Relevance and Role of Neuronal AT1 Receptors in ADAM17-Mediated ACE2 Shedding in Neurogenic Hypertension.
Combination of tumor necrosis factor-alpha ablation and matrix metalloproteinase inhibition prevents heart failure after pressure overload in tissue inhibitor of metalloproteinase-3 knock-out mice.
Comparison of properties of tumor necrosis factor-alpha converting enzyme (TACE) and some matrix metalloproteases (MMPs) in catalytic domains.
Constitutive alpha-secretase cleavage of the beta-amyloid precursor protein in the furin-deficient LoVo cell line: involvement of the pro-hormone convertase 7 and the disintegrin metalloprotease ADAM10.
Constitutive shedding of the amyloid precursor protein ectodomain is up-regulated by tumour necrosis factor-alpha converting enzyme.
Continuous real-time measurement of tumor necrosis factor-alpha converting enzyme activity on live cells.
Contribution of ADAM17 and related ADAMs in cardiovascular diseases.
Critical role of the disintegrin metalloprotease ADAM17 for intestinal inflammation and regeneration in mice.
Cross-talk between G protein-coupled receptor and epidermal growth factor receptor signaling pathways contributes to growth and invasion of head and neck squamous cell carcinoma.
Crystal structure of the catalytic domain of human tumor necrosis factor-alpha-converting enzyme.
Current concepts in the pathogenesis of meningitis caused by Streptococcus pneumoniae.
Current strategies exploiting NK-cell therapy to treat haematologic malignancies.
Cyclooxygenase-2 transactivates the epidermal growth factor receptor through specific E-prostanoid receptors and tumor necrosis factor-alpha converting enzyme.
CYP3A induction by N-hydroxyformamide tumor necrosis factor-alpha converting enzyme/matrix metalloproteinase inhibitors use of a pregname X receptor activation assay and primary hepatocyte culture for assessing induction potential in humans.
Deciphering the Role of the ADAM17-Dependent Secretome in Cell Signaling.
Decoding the enigma of antiviral crisis: Does one target molecule regulate all?
Defective valvulogenesis in HB-EGF and TACE-null mice is associated with aberrant BMP signaling.
Deletions in the cytoplasmic domain of iRhom1 and iRhom2 promote shedding of the TNF receptor by the protease ADAM17.
Delineating the molecular basis of the inactivity of tissue inhibitor of metalloproteinase-2 against tumor necrosis factor-alpha-converting enzyme.
Design of selective and soluble inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).
Design strategies for the identification of MMP-13 and Tace inhibitors.
Design, synthesis, and evaluation of benzothiadiazepine hydroxamates as selective tumor necrosis factor-alpha converting enzyme inhibitors.
Development of predictive 3D-QSAR CoMFA and CoMSIA models for beta-aminohydroxamic acid-derived tumor necrosis factor-alpha converting enzyme inhibitors.
Development of predictive pharmacophore model for in silico screening, and 3D QSAR CoMFA and CoMSIA studies for lead optimization, for designing of potent tumor necrosis factor alpha converting enzyme inhibitors.
Developmental expression of metalloproteases ADAM 9, 10, and 17 becomes restricted to divergent pancreatic compartments.
Diagnostic and prognostic value of a disintegrin and metalloproteinase-17 in patients with gliomas.
Differential expression of plasminogen activator inhibitor-1, tumor necrosis factor-alpha, TNF-alpha converting enzyme and ADAMTS family members in murine fat territories.
Differential regulation of TROP2 release by PKC isoforms through vesicles and ADAM17.
Differential regulation of tumor necrosis factor-alpha-converting enzyme and angiotensin-converting enzyme by type I and II interferons in human normal and leukemic myeloid cells.
Differential shedding of transmembrane neuregulin isoforms by the tumor necrosis factor-alpha-converting enzyme.
Differential surface expression of ADAM10 and ADAM17 on human T lymphocytes and tumor cells.
Differentiation-induced skin cancer suppression by FOS, p53, and TACE/ADAM17.
Discovery of gamma-lactam hydroxamic acids as selective inhibitors of tumor necrosis factor alpha converting enzyme: design, synthesis, and structure-activity relationships.
Discovery of low nanomolar non-hydroxamate inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).
Discovery of N-hydroxy-2-(2-oxo-3-pyrrolidinyl)acetamides as potent and selective inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).
Discovery of novel hydantoins as selective non-hydroxamate inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).
Discovery of novel hydroxamates as highly potent tumor necrosis factor-alpha converting enzyme inhibitors. Part II: Optimization of the S3' pocket.
Discovery of novel hydroxamates as highly potent tumor necrosis factor-alpha converting enzyme inhibitors: part I--discovery of two binding modes.
Discovery of selective hydroxamic acid inhibitors of tumor necrosis factor-alpha converting enzyme.
Discovery of selective phosphonamide-based inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).
Disruption of TACE-filamin interaction can inhibit TACE-mediated ectodomain shedding.
Dissociated presenilin-1 and TACE processing of ErbB4 in lung alveolar type II cell differentiation.
Distance dependent shedding of IL-6R.
Distinct ADAM metalloproteinases regulate G protein-coupled receptor-induced cell proliferation and survival.
Diverse roles of matrix metalloproteinases and tissue inhibitors of metalloproteinases in neuroinflammation and cerebral ischemia.
Does Adam17 cause the destruction of anchoring fibers via shedding tumor necrosis factor ? in bullous pemphigoid and dermatitis herpetiformis?
Doxycycline reduces mortality and injury to the brain and cochlea in experimental pneumococcal meningitis.
Drosophila TIMP is a potent inhibitor of MMPs and TACE: similarities in structure and function to TIMP-3.
Ectodomain cleavage of ErbB-4: characterization of the cleavage site and m80 fragment.
Ectodomain shedding of preadipocyte factor 1 (Pref-1) by tumor necrosis factor alpha converting enzyme (TACE) and inhibition of adipocyte differentiation.
Ectodomain shedding of the EGF-receptor ligand epigen is mediated by ADAM17.
Ectodomain shedding of the glycoprotein GP of Ebola virus.
Effect of Clarithromycin on the Expression of UL16-Binding Protein 2 in Human Cells.
Effect of DPC 333 [(2R)-2-{(3R)-3-amino-3-[4-(2-methylquinolin-4-ylmethoxy)phenyl]-2-oxopyrrolidin-1-yl}-N-hydroxy-4-methylpentanamide], a human tumor necrosis factor alpha-converting enzyme inhibitor, on the disposition of methotrexate: a transporter-based drug-drug interaction case study.
Effect of pro-inflammatory stimuli on mucin expression and inhibition by secretory leucoprotease inhibitor.
Effect of tumor necrosis factor-alpha converting enzyme (TACE) and metalloprotease inhibitor on amyloid precursor protein metabolism in human neurons.
EGFR-Dependent IL8 Production by Airway Epithelial Cells After Exposure to the Food Flavoring Chemical 2,3-Butanedione.
Endoproteolysis of beta-secretase (beta-site amyloid precursor protein-cleaving enzyme) within its catalytic domain. A potential mechanism for regulation.
Enhanced expression of TACE contributes to elevated levels of sVCAM-1 in endometriosis.
EpCAM is decreased but is still present in uterine epithelial cells during early pregnancy in the rat: potential mechanism for maintenance of mucosal integrity during implantation.
Epithelial cell adhesion molecule fragments and signaling in primary human liver cells.
Epithelial Cell-Derived a Disintegrin and Metalloproteinase-17 Confers Resistance to Colonic Inflammation Through EGFR Activation.
ErbB-4 and TNF-alpha converting enzyme localization to membrane microdomains.
ERK-mediated phosphorylation of Thr735 in TNFalpha-converting enzyme and its potential role in TACE protein trafficking.
Essential roles of IL-6 trans-signaling in colonic epithelial cells, induced by the IL-6/soluble-IL-6 receptor derived from lamina propria macrophages, on the development of colitis-associated premalignant cancer in a murine model.
Evaluation of Proteoforms of the Transmembrane Chemokines CXCL16 and CX3CL1, Their Receptors, and Their Processing Metalloproteinases ADAM10 and ADAM17 in Proliferative Diabetic Retinopathy.
Evidence for a critical role of the tumor necrosis factor alpha convertase (TACE) in ectodomain shedding of the p75 neurotrophin receptor (p75NTR).
Evidence for an interaction of the metalloprotease-disintegrin tumour necrosis factor alpha convertase (TACE) with mitotic arrest deficient 2 (MAD2), and of the metalloprotease-disintegrin MDC9 with a novel MAD2-related protein, MAD2beta.
Evidence that tumor necrosis factor alpha converting enzyme is involved in regulated alpha-secretase cleavage of the Alzheimer amyloid protein precursor.
Exogenous nitric oxide inhibits shedding of ADAM17 substrates.
Expression and protein chemistry yielding crystallization of the catalytic domain of ADAM17 complexed with a hydroxamate inhibitor.
Expression of ADAM Proteases in Bladder Cancer Patients with BCG Failure: A Pilot Study.
Expression of ADAMs (a disintegrin and metalloproteases) and TIMP-3 (tissue inhibitor of metalloproteinase-3) in human prostatic adenocarcinomas.
Expression of Migration-Related Genes in Human Colorectal Cancer and Activity of a Disintegrin and Metalloproteinase 17.
Expression of the ectodomain-releasing protease ADAM17 is directly regulated by the osteosarcoma and bone-related transcription factor RUNX2.
Expression of TNFalpha and its receptors R1 and R2 in human alveolar epithelial cells exposed to organic dust and the effects of 8-bromo-cAMP and protein kinase A modulation.
Expression of tumor necrosis factor alpha converting enzyme in endocrine cancers.
Expression of tumor necrosis factor-alpha converting enzyme in liver regeneration after partial hepatectomy.
Expression of tumor necrosis factor-alpha--converting enzyme and tumor necrosis factor-alpha in human myocarditis.
Extracellular Juxtamembrane Segment of ADAM17 Interacts with Membranes and Is Essential for Its Shedding Activity.
Extracellular phosphorylation of collagen XVII by ecto-casein kinase 2 inhibits ectodomain shedding.
Extracellular signal-regulated kinase phosphorylates tumor necrosis factor alpha-converting enzyme at threonine 735: a potential role in regulated shedding.
Free Energy Calculations on Snake Venom Metalloproteinase BaP1.
Full-length and N-TIMP-3 display equal inhibitory activities toward TNF-alpha convertase.
Functional analysis of the domain structure of tumor necrosis factor-alpha converting enzyme.
Functional Characterization of Colon Cancer-Associated Mutations in ADAM17: Modifications in the Pro-Domain Interfere with Trafficking and Maturation.
Functional Characterization of Colon-Cancer-Associated Variants in ADAM17 Affecting the Catalytic Domain.
Functionally confirmed compound heterozygous ADAM17 missense loss-of-function variants cause neonatal inflammatory skin and bowel disease 1.
Gallic acid reduces cell viability, proliferation, invasion and angiogenesis in human cervical cancer cells.
Gene silencing of TACE enhances plaque stability and improves vascular remodeling in a rabbit model of atherosclerosis.
Genetic Association Between NGFR, ADAM17 Gene Polymorphism, and Parkinson's Disease in the Chinese Han Population.
Genetic mapping of mouse tumor necrosis factor-alpha converting enzyme (TACE) to chromosome 12.
Genotypic and phenotypic characterization of side population of gastric cancer cell lines.
Glutamate-dependent ectodomain shedding of neuregulin-1 type II precursors in rat forebrain neurons.
Glycoprotein 130 signaling regulates Notch1 expression and activation in the self-renewal of mammalian forebrain neural stem cells.
Glycosylation of a disintegrin and metalloprotease 17 affects its activity and inhibition.
Green tea epigallocatechin-3-gallate (EGCG) modulates amyloid precursor protein cleavage and reduces cerebral amyloidosis in Alzheimer transgenic mice.
Growth hormone receptor is a target for presenilin-dependent gamma-secretase cleavage.
Harnessing the natural inhibitory domain to control TNF? Converting Enzyme (TACE) activity in vivo.
Heparin-binding epidermal growth factor-like growth factor signaling in flow-induced arterial remodeling.
High molecular weight hyaluronic acid down-regulates the gene expression of osteoarthritis-associated cytokines and enzymes in fibroblast-like synoviocytes from patients with early osteoarthritis.
High-resolution crystal structure of the snake venom metalloproteinase BaP1 complexed with a peptidomimetic: insight into inhibitor binding.
Highly water-soluble matrix metalloproteinases inhibitors and their effects in a rat adjuvant-induced arthritis model.
HPP1 Ectodomain Shedding is Mediated by ADAM17 and is Necessary for Tumor Suppression in Colon Cancer.
Human airway trypsin-like protease induces amphiregulin release through a mechanism involving protease-activated receptor-2-mediated ERK activation and TNF alpha-converting enzyme activity in airway epithelial cells.
Human breast cancer-associated fibroblasts enhance cancer cell proliferation through increased TGF-? cleavage by ADAM17.
Human colonic myocytes are involved in postischemic inflammation through ADAM17-dependent TNFalpha production.
Human placental trophoblasts secrete a disintegrin metalloproteinase very similar to the insulin-like growth factor binding protein-3 protease in human pregnancy serum.
Human renal cancer cells express a novel membrane-bound interleukin-15 that induces, in response to the soluble interleukin-15 receptor alpha chain, epithelial-to-mesenchymal transition.
Huperzine A regulates amyloid precursor protein processing via protein kinase C and mitogen-activated protein kinase pathways in neuroblastoma SK-N-SH cells over-expressing wild type human amyloid precursor protein 695.
Hydantoins, triazolones, and imidazolones as selective non-hydroxamate inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).
Hypothalamic tumor necrosis factor-alpha converting enzyme mediates excitatory amino acid-dependent neuron-to-glia signaling in the neuroendocrine brain.
Hypothesis: Alpha-1-antitrypsin is a promising treatment option for COVID-19.
Hypoxia-inducible factor 1alpha (HIF-1alpha)-mediated hypoxia increases BACE1 expression and beta-amyloid generation.
Hypoxia-inducible factor mediates hypoxic and tumor necrosis factor alpha-induced increases in tumor necrosis factor-alpha converting enzyme/ADAM17 expression by synovial cells.
Identification and characterization of human endometase (Matrix metalloproteinase-26) from endometrial tumor.
Identification of a selectivity determinant for inhibition of tumor necrosis factor-alpha converting enzyme by comparative modeling.
Identification of ligand-induced proteolytic cleavage and ectodomain shedding of VEGFR-1/FLT1 in leukemic cancer cells.
Identification of SAP97 as an intracellular binding partner of TACE.
Impact of IGF-1R/EGFR cross-talks on hepatoma cell sensitivity to gefitinib.
Impaired trafficking and activation of tumor necrosis factor-alpha-converting enzyme in cell mutants defective in protein ectodomain shedding.
Implication of TNF-alpha convertase (TACE/ADAM17) in inducible nitric oxide synthase expression and inflammation in an experimental model of colitis.
Implications of ADAM17 activation for hyperglycaemia, obesity and type 2 diabetes.
Improved Synthesis of ADAM10 Inhibitor GI254023X.
In Silico Screening for Anti-Inflammatory Bioactive Molecules from Ayurvedic Decoction, Balaguluchyadi Kashayam.
In situ evidence of involvement of Schwann cells in ulcerative colitis: autocrine and paracrine signaling by A disintegrin and metalloprotease-17-mediated tumor necrosis factor alpha production.
In-silico evidence of ADAM metalloproteinase pathology in cancer signaling networks.
Inactivating mutations block the tumor necrosis factor-alpha-converting enzyme in the early secretory pathway.
Increased expression of ADAM12 and ADAM17 genes in laser-capture microdissected breast cancers and correlations with clinical and pathological characteristics.
Increased expression of ALCAM/CD166 in pancreatic cancer is an independent prognostic marker for poor survival and early tumour relapse.
Increased expression of tumor necrosis factor-alpha converting enzyme and tumor necrosis factor-alpha in peripheral blood mononuclear cells in patients with advanced congestive heart failure.
Increased tumor necrosis factor alpha-converting enzyme activity induces insulin resistance and hepatosteatosis in mice.
Induction of TNF-alpha-converting enzyme-ectodomain shedding by pathogenic autoantibodies.
Inflammatory skin and bowel disease linked to ADAM17 deletion.
Inhibition of ADAM17 reduces hypoxia-induced brain tumor cell invasiveness.
Inhibition of metalloproteinases enhances the internalization of anti-CD30 antibody Ki-3 and the cytotoxic activity of Ki-3 immunotoxin.
Inhibition of Notch pathway arrests PTEN-deficient advanced prostate cancer by triggering p27-driven cellular senescence.
Inhibition of the tumor necrosis factor-alpha-converting enzyme by its pro domain.
Inhibition of tumor necrosis factor-alpha-converting enzyme by a selective antagonist protects brain from focal ischemic injury in rats.
Inhibitors of TACE and Caspase-1 as anti-inflammatory drugs.
Innate immune mucin production via epithelial cell surface signaling: relationship to allergic disease.
iNOS promotes CD24+CD133+ liver cancer stem cell phenotype through a TACE/ADAM17-dependent Notch signaling pathway.
Insights into desmosome biology from inherited human skin disease and cardiocutaneous syndromes.
Interleukin-11-driven gastric tumourigenesis is independent of trans-signalling.
Interleukin-4 antagonizes oncostatin M and transforming growth factor beta-induced responses in articular chondrocytes.
Interleukin-6 receptor shedding is enhanced by interleukin-1beta and tumor necrosis factor alpha and is partially mediated by tumor necrosis factor alpha-converting enzyme in osteoblast-like cells.
Interphotoreceptor Retinoid-Binding Protein Mitigates Cellular Oxidative Stress and Mitochondrial Dysfunction Induced by All-trans-Retinal.
Intracellular maturation and transport of tumor necrosis factor alpha converting enzyme.
Investigation of the role of TNF-? converting enzyme (TACE) in the inhibition of cell surface and soluble TNF-? production by acute ethanol exposure.
Involvement of NF-kappaB-mediated maturation of ADAM-17 in the invasion of oral squamous cell carcinoma.
Ionizing radiation increases the endothelial permeability and the transendothelial migration of tumor cells through ADAM10-activation and subsequent degradation of VE-cadherin.
iRhom2 and TNF: Partners or enemies?
iRhom2 inhibits bile duct obstruction-induced liver fibrosis.
Key feature of the catalytic cycle of TNF-alpha converting enzyme involves communication between distal protein sites and the enzyme catalytic core.
L-Selectin Expression Is Influenced by Phosphatase Activity in Chronic Lymphocytic Leukemia.
LC-MS Based Cleavage Site Profiling of the Proteases ADAM10 and ADAM17 Using Proteome-Derived Peptide Libraries.
Lewis antigen?negative pancreatic cancer: An aggressive subgroup.
Localization of tumour necrosis factor-alpha converting enzyme in normal human skin.
Loss of ectodomain shedding due to mutations in the metalloprotease and cysteine-rich/disintegrin domains of the tumor necrosis factor-alpha converting enzyme (TACE).
Mammalian iRhoms have distinct physiological functions including an essential role in TACE regulation.
Mass spectrometry-based proteomics revealed Glypican-1 as a novel ADAM17 substrate.
Matrix metalloproteinases and TACE play a role in the pathogenesis of endometriosis.
Mechanisms of site-specific dephosphorylation and kinase opposition imposed by PP2A regulatory subunits.
Meltrin beta (ADAM19) mediates ectodomain shedding of Neuregulin beta1 in the Golgi apparatus: fluorescence correlation spectroscopic observation of the dynamics of ectodomain shedding in living cells.
Membrane-anchored CD40 is processed by the tumor necrosis factor-alpha-converting enzyme. Implications for CD40 signaling.
Metalloprotease-dependent protransforming growth factor-alpha ectodomain shedding in the absence of tumor necrosis factor-alpha-converting enzyme.
Metalloprotease-mediated GH receptor proteolysis and GHBP shedding. Determination of extracellular domain stem region cleavage site.
Metalloprotease-mediated tumor cell shedding of B7-H6, the ligand of the natural killer cell-activating receptor NKp30.
Metalloproteinase- and gamma-secretase-mediated cleavage of protein-tyrosine phosphatase receptor type Z.
Metalloproteinase-dependent cleavage of neuregulin and autocrine stimulation of vascular endothelial cells.
Metalloproteinases ADAM10 and ADAM17 Mediate Migration and Differentiation in Glioblastoma Sphere-Forming Cells.
Metalloproteinases and the modulation of GH signaling.
Metalloproteinases and transforming growth factor-alpha mediate substance P-induced mitogen-activated protein kinase activation and proliferation in human colonocytes.
Metastasis-associated C4.4A, a GPI-anchored protein cleaved by ADAM10 and ADAM17.
mGluR1/5-dependent long-term depression requires the regulated ectodomain cleavage of neuronal pentraxin NPR by TACE.
Mice heterozygous for tumor necrosis factor-alpha converting enzyme are protected from obesity-induced insulin resistance and diabetes.
Microparticles generated during chronic cerebral ischemia increase the permeability of microvascular endothelial barriers in vitro.
MicroRNA-122, a tumor suppressor microRNA that regulates intrahepatic metastasis of hepatocellular carcinoma.
MicroRNA-145 Targets the Metalloprotease ADAM17 and Is Suppressed in Renal Cell Carcinoma Patients.
MicroRNA-145 targets YES and STAT1 in colon cancer cells.
MicroRNA-152 targets ADAM17 to suppress NSCLC progression.
miR-221/222 control luminal breast cancer tumor progression by regulating different targets.
MiR-338-3p inhibits cell migration and invasion in human hypopharyngeal cancer via downregulation of ADAM17.
Mitogenic activity and signaling mechanism of 2-(14,15- epoxyeicosatrienoyl)glycerol, a novel cytochrome p450 arachidonate metabolite.
Modification of proteolytic activity matrix analysis (PrAMA) to measure ADAM10 and ADAM17 sheddase activities in cell and tissue lysates.
Modulation of autocrine TNF-alpha-stimulated matrix metalloproteinase 9 (MMP-9) expression by mitogen-activated protein kinases in THP-1 monocytic cells.
Molecular modeling and biological effects of peptidomimetic inhibitors of TACE activity.
Molecular Pathways: Receptor Ectodomain Shedding in Treatment, Resistance, and Monitoring of Cancer.
Molecular Profiling of ADAM12 and ADAM17 Genes in Human Malignant Melanoma.
Molecular switch in human diseases-disintegrin and metalloproteinases, ADAM17.
More light on cancer and COVID-19 reciprocal interaction.
MT1-MMP mediates MUC1 shedding independent of TACE/ADAM17.
Multiple Acquired Renal Carcinoma Tumor Capabilities Abolished upon Silencing of ADAM17.
Multiple metalloproteinases process protransforming growth factor-alpha (proTGF-alpha).
Nardilysin enhances ectodomain shedding of heparin-binding epidermal growth factor-like growth factor through activation of tumor necrosis factor-alpha-converting enzyme.
Natural soluble interleukin-15Ralpha is generated by cleavage that involves the tumor necrosis factor-alpha-converting enzyme (TACE/ADAM17).
Nectin-4, a new serological breast cancer marker, is a substrate for tumor necrosis factor-alpha-converting enzyme (TACE)/ADAM-17.
Neuronal RA175/SynCAM1 isoforms are processed by tumor necrosis factor-alpha-converting enzyme (TACE)/ADAM17-like proteases.
New alpha-substituted succinate-based hydroxamic acids as TNFalpha convertase inhibitors.
Niaspan treatment increases tumor necrosis factor-alpha-converting enzyme and promotes arteriogenesis after stroke.
NMDA receptor activation inhibits alpha-secretase and promotes neuronal amyloid-beta production.
Non-hydroxamate 5-phenylpyrimidine-2,4,6-trione derivatives as selective inhibitors of tumor necrosis factor-alpha converting enzyme.
Nonischemic lung injury by mediators from unilateral ischemic reperfused lung: ameliorating effect of tumor necrosis factor-alpha-converting enzyme inhibitor.
Novel methods and strategies in the discovery of TACE inhibitors.
Nox1/4 dual inhibitor GKT137831 attenuates hypertensive cardiac remodelling associating with the inhibition of ADAM17-dependent proinflammatory cytokines-induced signalling pathways in the rats with abdominal artery constriction.
Oncogenic Kras promotes chemotherapy-induced growth factor shedding via ADAM17.
Oxidation of cholesterol by amyloid precursor protein and beta-amyloid peptide.
P2Y2 nucleotide receptors mediate metalloprotease-dependent phosphorylation of epidermal growth factor receptor and ErbB3 in human salivary gland cells.
p38 mitogen-activated protein kinase activation during platelet storage: consequences for platelet recovery and hemostatic function in vivo.
p38 mitogen-activated protein kinase-dependent tumor necrosis factor-alpha-converting enzyme is important for liver injury in hepatotoxic interaction between lipopolysaccharide and ranitidine.
Pathological neovascularization is reduced by inactivation of ADAM17 in endothelial cells but not in pericytes.
Pharmacokinetics and pharmacodynamics of DPC 333 ((2R)-2-((3R)-3-amino-3{4-[2-methyl-4-quinolinyl) methoxy] phenyl}-2-oxopyrrolidinyl)-N-hydroxy-4-methylpentanamide)), a potent and selective inhibitor of tumor necrosis factor alpha-converting enzyme in rodents, dogs, chimpanzees, and humans.
Phorbol 12-myristate 13-acetate-induced ectodomain shedding and phosphorylation of the human meprinbeta metalloprotease.
Phorbol ester-induced apoptosis in prostate cancer cells via autocrine activation of the extrinsic apoptotic cascade: a key role for protein kinase C delta.
Plasma kallikrein promotes epidermal growth factor receptor transactivation and signaling in vascular smooth muscle through direct activation of protease-activated receptors.
Platelet-mediated shedding of NKG2D ligands impairs NK cell immune-surveillance of tumor cells.
Polo-like kinase 2, a novel ADAM17 signaling component, regulates tumor necrosis factor ? ectodomain shedding.
Polymorphisms of the tumor necrosis factor-alpha (TNF) and the TNF-alpha converting enzyme (TACE/ADAM17) genes in relation to cardiovascular mortality: the AtheroGene study.
Porphyromonas gingivalis stimulates TACE production by T cells.
Post-transcriptional up-regulation of ADAM17 upon epidermal growth factor receptor activation and in breast tumors.
Potent arylsulfonamide inhibitors of tumor necrosis factor-alpha converting enzyme able to reduce activated leukocyte cell adhesion molecule shedding in cancer cell models.
Potent, selective, orally bioavailable inhibitors of tumor necrosis factor-alpha converting enzyme (TACE): discovery of indole, benzofuran, imidazopyridine and pyrazolopyridine P1' substituents.
Preconditioning with sublethal ischemia or intermittent normobaric hyperoxia up-regulates glutamate transporters and tumor necrosis factor-alpha converting enzyme in the rat brain.
Pref-1 interacts with fibronectin to inhibit adipocyte differentiation.
Pref-1, a preadipocyte secreted factor that inhibits adipogenesis.
Presenilin-dependent gamma-secretase processing regulates multiple ERBB4/HER4 activities.
Pro-tumor necrosis factor-alpha processing activity is tightly controlled by a component that does not affect notch processing.
Production of the soluble form of KIT, s-KIT, abolishes stem cell factor-induced melanogenesis in human melanocytes.
Prognostic significance of ADAM17 expression in patients with gastric cancer who underwent curative gastrectomy.
Prognostic Significance of ADAM17 for Gastric Cancer Survival: A Meta-Analysis.
Prognostic value of ADAM17 in human gastric cancer.
Pronounced diversity in electronic and chemical properties between the catalytic zinc sites of tumor necrosis factor-alpha-converting enzyme and matrix metalloproteinases despite their high structural similarity.
Protease inhibitors of the sulfonamide type: anticancer, antiinflammatory, and antiviral agents.
Protein kinase C (PKC) increases TACE/ADAM17 enzyme activity in porcine ovarian somatic cells, which is essential for granulosa cell luteinization and oocyte maturation.
Proteolytic cleavage and phosphorylation of a tumor-associated ErbB4 isoform promote ligand-independent survival and cancer cell growth.
Proteomic identification of desmoglein 2 and activated leukocyte cell adhesion molecule as substrates of ADAM17 and ADAM10 by difference gel electrophoresis.
Pulmonary hypoplasia in mice lacking tumor necrosis factor-alpha converting enzyme indicates an indispensable role for cell surface protein shedding during embryonic lung branching morphogenesis.
Rapid and sensitive detection of the activity of ADAM17 using a graphene oxide-based fluorescence sensor.
Reactive site mutations in tissue inhibitor of metalloproteinase-3 disrupt inhibition of matrix metalloproteinases but not tumor necrosis factor-alpha-converting enzyme.
Recent Advances in ADAM17 Research: A Promising Target for Cancer and Inflammation.
Reduced CD62L Expression on T Cells and Increased Soluble CD62L Levels Predict Molecular Response to Tyrosine Kinase Inhibitor Therapy in Early Chronic-Phase Chronic Myelogenous Leukemia.
Reduction of Serum ADAM17 Level Accompanied with Decreased Cytokines after Abatacept Therapy in Patients with Rheumatoid Arthritis.
Regulation of A disintegrin and metalloproteinase (ADAM) family sheddases ADAM10 and ADAM17: The emerging role of tetraspanins and rhomboids.
Regulation of interleukin-8 via an airway epithelial signaling cascade.
Regulation of membrane metalloproteolytic cleavage of L-selectin (CD62l) by the epidermal growth factor domain.
Regulation of peritoneal and systemic neutrophil-derived tumor necrosis factor-alpha release in patients with severe peritonitis: role of tumor necrosis factor-alpha converting enzyme cleavage.
Regulation of Platelet-Derived ADAM17: A Biomarker Approach for Breast Cancer?
Relaxed specificity of matrix metalloproteinases (MMPS) and TIMP insensitivity of tumor necrosis factor-alpha (TNF-alpha) production suggest the major TNF-alpha converting enzyme is not an MMP.
Release of soluble tumor necrosis factor receptor 1 from corneal epithelium by TNF-alpha converting enzyme dependent ectodomain shedding.
Removal of cell surface heparan sulfate increases TACE activity and cleavage of ErbB4 receptor.
Role of ADAM17 as a regulatory checkpoint of CD16A in NK cells and as a potential target for cancer immunotherapy.
Role of ADAM17 in kidney disease.
Role of ADAMs in cancer formation and progression.
Role of TIMPs (tissue inhibitors of metalloproteinases) in pericellular proteolysis: the specificity is in the detail.
Rosmarinic acid inhibits proliferation and migration, promotes apoptosis and enhances cisplatin sensitivity of melanoma cells through inhibiting ADAM17/EGFR/AKT/GSK3? axis.
Screening of TACE peptide inhibitors from phage display peptide library.
Secretome Signature Identifies ADAM17 as Novel Target for Radiosensitization of Non-Small Cell Lung Cancer.
Selective and Specific Regulation of Ectodomain Shedding of Angiotensin-converting Enzyme 2 by Tumor Necrosis Factor {alpha}-converting Enzyme.
Selective roles for tumor necrosis factor alpha-converting enzyme/ADAM17 in the shedding of the epidermal growth factor receptor ligand family: the juxtamembrane stalk determines cleavage efficiency.
Semaphorin 7A as a potential immune regulator and promising therapeutic target in rheumatoid arthritis.
Senescence-associated release of transmembrane proteins involves proteolytic processing by ADAM17 and microvesicle shedding.
Serotonin stimulates platelet receptor shedding by tumor necrosis factor-alpha-converting enzyme (ADAM17).
Severity of coronary artery stenosis is associated with a polymorphism in the CXCL16/SR-PSOX gene.
Sheddase Activity of Tumor Necrosis Factor-{alpha} Converting Enzyme Is Increased and Prognostically Valuable in Head and Neck Cancer.
Shedding light on sheddases: role in growth and development.
Shedding of collagen XVII ectodomain depends on plasma membrane microenvironment.
Shedding of endogenous MHC class I-related chain molecules A and B (MICA and MICB) from different human tumor entities: Heterogeneous involvement of the a disintegrin and metalloproteases 10 and 17 (ADAM10 and ADAM17).
Shedding of the p75NTR neurotrophin receptor is modulated by lipid rafts.
Short hairpin RNA-mediated gene silencing of ADAM17 inhibits the growth of breast cancer MCF?7 cells in vitro and in vivo and its mechanism of action.
SLITRK1 Binds 14-3-3 and Regulates Neurite Outgrowth in a Phosphorylation-Dependent Manner.
Soluble Form of the (Pro)Renin Receptor Generated by Intracellular Cleavage by Furin Is Secreted in Plasma.
Soluble Interleukin IL-15Ralpha is generated by alternative splicing or proteolytic cleavage and forms functional complexes with IL-15.
Specific sequence elements are required for the expression of functional tumor necrosis factor-alpha-converting enzyme (TACE).
Src and ADAM-17-mediated shedding of transforming growth factor-alpha is a mechanism of acute resistance to TRAIL.
Stimulated release and functional activity of surface expressed metalloproteinase ADAM17 in exosomes.
Stimulated shedding of vascular cell adhesion molecule 1 (VCAM-1) is mediated by tumor necrosis factor-alpha-converting enzyme (ADAM 17).
Stimulation of platelet-derived growth factor receptor beta (PDGFRbeta) activates ADAM17 and promotes metalloproteinase-dependent cross-talk between the PDGFRbeta and epidermal growth factor receptor (EGFR) signaling pathways.
Stimulation-induced down-regulation of tumor necrosis factor-alpha converting enzyme.
Store-operated calcium entry (SOCE) contributes to phosphorylation of p38 MAPK and suppression of TNF-? signalling in the intestinal epithelial cells.
Strategies to Target ADAM17 in Disease: From its Discovery to the iRhom Revolution.
Stroke-induced subventricular zone proliferation is promoted by tumor necrosis factor-alpha-converting enzyme protease activity.
Structural modeling defines transmembrane residues in ADAM17 that are crucial for Rhbdf2-ADAM17-dependent proteolysis.
Structure and functions of tumor necrosis factor-alpha converting enzyme.
Structure-function relationship and role of tumor necrosis factor-alpha-converting enzyme in the down-regulation of L-selectin by non-steroidal anti-inflammatory drugs.
Structures of adamalysin II with peptidic inhibitors. Implications for the design of tumor necrosis factor alpha convertase inhibitors.
Substitution of methionine 435 with leucine, isoleucine, and serine in tumor necrosis factor alpha converting enzyme inactivates ectodomain shedding activity.
Synthesis and in vitro Evaluation of ADAM10 and ADAM17 Highly Selective Bioimaging Probes.
Synthesis and structure-activity relationships of 4-alkynyloxy phenyl sulfanyl, sulfinyl, and sulfonyl alkyl hydroxamates as tumor necrosis factor-alpha converting enzyme and matrix metalloproteinase inhibitors.
Synthesis of [(3) H], [(13) C3 , (15) N], and [(14) C]SCH 900567: an inhibitor of TNF-? (tumor necrosis factor alpha) converting enzyme (TACE).
TACE activation by MAPK-mediated regulation of cell surface dimerization and TIMP3 association.
TACE cleaves neogenin to desensitize cortical neurons to the repulsive guidance molecule.
TACE is required for fetal murine cardiac development and modeling.
TACE is required for the activation of the EGFR by TGF-alpha in tumors.
TACE-dependent TGF? shedding drives triple-negative breast cancer cell invasion.
TACE/ADAM-17 enzymatic activity is increased in response to cellular stimulation.
TACE/ADAM-17 maturation and activation of sheddase activity require proprotein convertase activity.
TACE/ADAM17 is essential for oligodendrocyte development and CNS myelination.
TACE/ADAM17 processing of EGFR ligands indicates a role as a physiological convertase.
TACE: a new target in epidermal growth factor receptor dependent tumors.
Tailoring tissue inhibitor of metalloproteinases-3 to overcome the weakening effects of the cysteine-rich domains of tumour necrosis factor-alpha converting enzyme.
Targeted overexpression of noncleavable and secreted forms of tumor necrosis factor provokes disparate cardiac phenotypes.
Targeted overexpression of transmembrane tumor necrosis factor provokes a concentric cardiac hypertrophic phenotype.
Targeted truncation of the ADAM17 cytoplasmic domain in mice results in protein destabilization and a hypomorphic phenotype.
Targeting ADAM17 inhibits human colorectal adenocarcinoma progression and tumor-initiating cell frequency.
Targeting ADAM17 Sheddase Activity In Cancer.
Targeting the sheddase activity of ADAM17 by an anti-ADAM17 antibody D1(A12) inhibits head and neck squamous cell carcinoma cell proliferation and motility via blockage of bradykinin induced HERs transactivation.
Tetraspanin CD9 interacts with ?-secretase to enhance its oncogenic function in pancreatic cancer.
The "A Disintegrin And Metalloproteases" ADAM10 and ADAM17: Novel drug targets with therapeutic potential?
The ADAM10 prodomain is a specific inhibitor of ADAM10 proteolytic activity and inhibits cellular shedding events.
The ADAM17 Protease Promotes Tobacco Smoke Carcinogen-induced Lung Tumourigenesis.
The ADAMs family of proteases as targets for the treatment of cancer.
The ADAMs family of proteases: new biomarkers and therapeutic targets for cancer?
The Antiatherogenic Effect of Fish Oil in Male Mice Is Associated with a Diminished Release of Endothelial ADAM17 and ADAM10 Substrates.
The C-terminal domains of TACE weaken the inhibitory action of N-TIMP-3.
The correlation between the expression of ADAM17, EGFR and Ki-67 in malignant gliomas.
The disintegrin ADAM9 indirectly contributes to the physiological processing of cellular prion by modulating ADAM10 activity.
The disintegrin domain of ADAM17 antagonises fibroblast?carcinoma cell interactions.
The disintegrin-like metalloproteinase ADAM10 is involved in constitutive cleavage of CX3CL1 (fractalkine) and regulates CX3CL1-mediated cell-cell adhesion.
The disintegrins ADAM10 and TACE contribute to the constitutive and phorbol ester-regulated normal cleavage of the cellular prion protein.
The good, the bad and the ugly substrates for ADAM10 and ADAM17 in brain pathology, inflammation and cancer.
The membrane-proximal domain of ADAM17 represents the putative molecular switch of its shedding activity operated by protein-disulfide isomerase.
The metalloprotease ADAM17 in inflammation and cancer.
The P2/P2' sites affect the substrate cleavage of TNF-? converting enzyme (TACE).
The Rhomboid Superfamily: Structural Mechanisms and Chemical Biology Opportunities.
The role of ADAM10 and ADAM17 in the ectodomain shedding of angiotensin converting enzyme and the amyloid precursor protein.
The role of ADAM17 during liver damage.
The role of ADAMs in disease pathophysiology.
The role of microRNA in metastatic colorectal cancer and its significance in cancer prognosis and treatment.
The role of NF-?B and Elk-1 in the regulation of mouse ADAM17 expression.
The shedding protease ADAM17: Physiology and pathophysiology.
The soluble alpha chain of interleukin-15 receptor: a proinflammatory molecule associated with tumor progression in head and neck cancer.
The sorting protein PACS-2 promotes ErbB signalling by regulating recycling of the metalloproteinase ADAM17.
The TACE zymogen: re-examining the role of the cysteine switch.
The transmembrane domain of TACE regulates protein ectodomain shedding.
The tumor necrosis factor-alpha converting enzyme (TACE): a unique metalloproteinase with highly defined substrate selectivity.
The unfolded protein response controls induction and activation of ADAM17/TACE by severe hypoxia and ER stress.
Therapeutic applications: natural killer cells in the clinic.
Therapeutic potential of ADAM17 modulation in gastric cancer through regulation of the EGFR and TNF-? signalling pathways.
Therapeutic potential of TACE inhibitors in stroke.
TIMP-3 ameliorates hepatic ischemia/reperfusion injury through inhibition of tumor necrosis factor-alpha-converting enzyme activity in rats.
TIMP-3 and MMP-3 contribute to delayed inflammation and hippocampal neuronal death following global ischemia.
Tissue inhibitor of matrix metalloproteinases-3 (TIMP-3) lacks involvement in bacterial collagenase-induced intracerebral hemorrhage in mouse.
Tissue inhibitor of metalloproteinase 3 deficiency causes hepatic steatosis and adipose tissue inflammation in mice.
TLR ligand-induced podosome disassembly in dendritic cells is ADAM17 dependent.
TNF? drives pulmonary arterial hypertension by suppressing the BMP type-II receptor and altering NOTCH signalling.
TNF?-Erk1/2 signaling pathway-regulated SerpinE1 and SerpinB2 are involved in lipopolysaccharide-induced porcine granulosa cell proliferation.
TNFR1 upregulation mediates tolerance after brain ischemic preconditioning.
Tobacco smoke-induced lung cell proliferation mediated by tumor necrosis factor alpha-converting enzyme and amphiregulin.
Total conversion of tissue inhibitor of metalloproteinase (TIMP) for specific metalloproteinase targeting: fine-tuning TIMP-4 for optimal inhibition of tumor necrosis factor-{alpha}-converting enzyme.
Transcription factor Sp1 induces ADAM17 and contributes to tumor cell invasiveness under hypoxia.
Transforming growth factor alpha (TGF-alpha) and other targets of tumor necrosis factor-alpha converting enzyme (TACE) in murine polycystic kidney disease.
Transforming growth factor beta induces clustering of HER2 and integrins by activating Src-focal adhesion kinase and receptor association to the cytoskeleton.
Tumor necrosis factor alpha converting enzyme: an encouraging target for various inflammatory disorders.
Tumor necrosis factor alpha-converting enzyme mediates MUC5AC mucin expression in cultured human airway epithelial cells.
Tumor necrosis factor-alpha converting enzyme (TACE) is a growth hormone binding protein (GHBP) sheddase: the metalloprotease TACE/ADAM-17 is critical for (PMA-induced) GH receptor proteolysis and GHBP generation.
Tumor necrosis factor-alpha converting enzyme (TACE) regulates epidermal growth factor receptor ligand availability.
Tumor necrosis factor-alpha converting enzyme in the human placenta throughout gestation.
Tumor necrosis factor-alpha converting enzyme is processed by proprotein-convertases to its mature form which is degraded upon phorbol ester stimulation.
Tumor necrosis factor-alpha converting enzyme.
Tumor necrosis factor-alpha converting enzyme/ADAM 17 mediates MUC1 shedding.
Tumor necrosis factor-alpha converting enzyme: Implications for ocular inflammatory diseases.
Tumor necrosis factor-alpha-converting enzyme (ADAM17) mediates GPIbalpha shedding from platelets in vitro and in vivo.
Tumor necrosis factor-alpha-converting enzyme (ADAM17) mediates the cleavage and shedding of fractalkine (CX3CL1).
Tumor necrosis factor-alpha-converting enzyme (TACE) levels in periodontal diseases.
Tumor necrosis factor-alpha-converting enzyme (TACE/ADAM-17) mediates the ectodomain cleavage of intercellular adhesion molecule-1 (ICAM-1).
Tumor necrosis factor-alpha-converting enzyme activities and tumor-associated macrophages in breast cancer.
Tumor necrosis factor-alpha-converting enzyme and tumor necrosis factor-alpha in human dilated cardiomyopathy.
Tumor necrosis factor-alpha-converting enzyme as a potential mediator of the influence of smoking on the response to treatment with narrowband ultraviolet B in psoriasis patients.
Tumor necrosis factor-alpha-converting enzyme controls surface expression of c-Kit and survival of embryonic stem cell-derived mast cells.
Tumor necrosis factor-alpha-converting enzyme is a key regulator of agonist-induced cardiac hypertrophy and fibrosis.
Tumor necrosis factor-alpha-converting enzyme is expressed in the inflamed peripheral nervous system.
Tumor necrosis factor-alpha-converting enzyme is required for cleavage of erbB4/HER4.
Tumor necrosis factor-alpha-converting enzyme mediates the inducible cleavage of fractalkine.
Tumor necrosis factor-alpha-converting enzyme: its role in community-acquired pneumonia.
Tumor-associated MICA is shed by ADAM proteases.
Tumor-derived fibulin-3 activates pro-invasive NF-?B signaling in glioblastoma cells and their microenvironment.
Tumorigenicity of cortical astrocyte cell line induced by the protease ADAM17.
Tumour necrosis factor alpha-converting enzyme mediates ectodomain shedding of Vps10p-domain receptor family members.
Tumour necrosis factor-alpha converting enzyme (TACE) activity in human colonic epithelial cells.
Tumour necrosis factor-alpha converting enzyme in human gestational tissues from pregnancies complicated by chorioamnionitis.
Tumour necrosis factor-alpha stimulates expression of TNF-alpha converting enzyme in endothelial cells.
Unaltered cleavage and secretion of angiotensin-converting enzyme in tumor necrosis factor-alpha-converting enzyme-deficient mice.
Up-regulated expression of ADAM17 in gastrointestinal stromal tumors: coexpression with EGFR and EGFR ligands.
Up-regulated expression of ADAM17 in human colon carcinoma: co-expression with EGFR in neoplastic and endothelial cells.
Up-regulation of TNF-alpha convertase (TACE/ADAM17) after oxygen-glucose deprivation in rat forebrain slices.
Upregulated Expression of ADAM17 Is a Prognostic Marker for Patients With Gastric Cancer.
Upregulation of ADAM-17 expression in active lesions in multiple sclerosis.
Upregulation of tumor necrosis factor receptor 1 and TNF-alpha converting enzyme during corneal wound healing.
Ursolic acid prevents angiotensin II-induced abdominal aortic aneurysm in apolipoprotein E-knockout mice.
VEGF-A stimulates ADAM17-dependent shedding of VEGFR2 and crosstalk between VEGFR2 and ERK signaling.
What Blood Temperature for an Ex Vivo Extracorporeal Circuit?
[Construction and identification of bait recombinant vector of tumor necrosis factor-alpha converting enzyme in the yeast two hybrid system].
[Inhibition of proliferation, adhesion and invasion ability of human lung carcinoma cell A549 by tumor necrosis factor-alpha converting enzyme (TACE)]
[Screening of TACE peptide inhibitors from a phage display random 15-peptide library by recombinant TACE ecotodomain]
[The structural features and inhibitors of tumor necrosis factor-alpha converting enzyme]
Nephrosis
Effects of Shenkangling intervention on the MAPK pathway in rats with doxorubicin-induced nephropathy.
Nervous System Diseases
Neuronal ADAM10 Promotes Outgrowth of Small-Caliber Myelinated Axons in the Peripheral Nervous System.
Neuralgia
Impaired mechanical, heat, and cold nociception in a murine model of genetic TACE/ADAM17 knockdown.
Neuroblastoma
Carnosic acid suppresses the production of amyloid-? 1-42 by inducing the metalloprotease gene TACE/ADAM17 in SH-SY5Y human neuroblastoma cells.
Phenanthroline impairs ?APP processing and expression, increases p53 protein levels and induces cell cycle arrest in human neuroblastoma cells.
Taiwan cobra phospholipase A2 elicits posttranscriptional up-regulation of ADAM17 in human neuroblastoma SK-N-SH cells.
Neurodegenerative Diseases
Activation of Kinin B1R Upregulates ADAM17 and Results in ACE2 Shedding in Neurons.
LC-MS Based Cleavage Site Profiling of the Proteases ADAM10 and ADAM17 Using Proteome-Derived Peptide Libraries.
The "A Disintegrin And Metalloproteases" ADAM10 and ADAM17: Novel drug targets with therapeutic potential?
Neuroinflammatory Diseases
Diverse roles of matrix metalloproteinases and tissue inhibitors of metalloproteinases in neuroinflammation and cerebral ischemia.
Functions of 'A disintegrin and metalloproteases (ADAMs)' in the mammalian nervous system.
The Gut-Brain Axis in Autism Spectrum Disorder: A Focus on the Metalloproteases ADAM10 and ADAM17.
Non-alcoholic Fatty Liver Disease
Hepatocyte specific TIMP3 expression prevents diet dependent fatty liver disease and hepatocellular carcinoma.
Obesity
ADAM17_i33708A>G polymorphism interacts with dietary n-6 polyunsaturated fatty acids to modulate obesity risk in the Genetics of Lipid Lowering Drugs and Diet Network study.
Altered tumor necrosis factor-alpha (TNF-alpha) processing in adipocytes and increased expression of transmembrane TNF-alpha in obesity.
Dendritic Cell-Restricted Progenitors Contribute to Obesity-Associated Airway Inflammation via Adam17-p38 MAPK-Dependent Pathway.
Implications of ADAM17 activation for hyperglycaemia, obesity and type 2 diabetes.
Role of Adipose Tissue Endothelial ADAM17 in Age-Related Coronary Microvascular Dysfunction.
The Role of iRhom2 in Metabolic and Cardiovascular-Related Disorders.
[The two sides of ADAM17 in inflammation: implications in atherosclerosis and obesity]
Osteoarthritis
ADAM-17 is expressed on rheumatoid arthritis fibroblast-like synoviocytes and regulates proinflammatory mediator expression and monocyte adhesion.
Design strategies for the identification of MMP-13 and Tace inhibitors.
TNF-alpha convertase enzyme from human arthritis-affected cartilage: isolation of cDNA by differential display, expression of the active enzyme, and regulation of TNF-alpha.
Osteosarcoma
Expression of the ectodomain-releasing protease ADAM17 is directly regulated by the osteosarcoma and bone-related transcription factor RUNX2.
Ovarian Neoplasms
ADAM metallopeptidase domain 17 (ADAM17) is naturally processed through major histocompatibility complex (MHC) class I molecules and is a potential immunotherapeutic target in breast, ovarian and prostate cancers.
ADAM17 inhibition enhances platinum efficiency in ovarian cancer.
ADAM17 Inhibition Increases the Impact of Cisplatin Treatment in Ovarian Cancer Spheroids.
Bisphenol-A and Nonylphenol Induce Apoptosis in Reproductive Tract Cancer Cell Lines by the Activation of ADAM17.
Clinical significance of heparin-binding epidermal growth factor-like growth factor and a disintegrin and metalloprotease 17 expression in human ovarian cancer.
Ectodomain shedding of the cell adhesion molecule Nectin-4 in ovarian cancer is mediated by ADAM10 and ADAM17.
Lysophosphatidic acid induces tumor necrosis factor-alpha to regulate a pro-inflammatory cytokine network in ovarian cancer.
Lysophosphatidic acid, a disintegrin and metalloprotease-17 and heparin-binding epidermal growth factor-like growth factor in ovarian cancer: the first word, not the last.
Metalloproteinases at the surface of small extrcellular vesicles in advanced ovarian cancer: Relationships with ascites volume and peritoneal canceromatosis index.
Nivolumab effectively inhibit platinum-resistant ovarian cancer cells via induction of cell apoptosis and inhibition of ADAM17 expression.
Selective Arylsulfonamide Inhibitors of ADAM-17: Hit Optimization and Activity in Ovarian Cancer Cell Models.
Pancreatic Neoplasms
A novel bispecific single-chain antibody for ADAM17 and CD3 induces T-cell-mediated lysis of prostate cancer cells.
Deciphering microRNA targets in pancreatic cancer using miRComb R package.
Increased expression of ALCAM/CD166 in pancreatic cancer is an independent prognostic marker for poor survival and early tumour relapse.
Parkinson Disease
Genetic Association Between NGFR, ADAM17 Gene Polymorphism, and Parkinson's Disease in the Chinese Han Population.
Pemphigoid, Bullous
Does Adam17 cause the destruction of anchoring fibers via shedding tumor necrosis factor ? in bullous pemphigoid and dermatitis herpetiformis?
Peptic Ulcer
ADAM proteases involved in inflammation are differentially altered in patients with gastritis or ulcer.
Periodontal Diseases
ADAM17 regulates TNF-? expression upon lipopolysaccharide stimulation in oral keratinocytes.
Periodontal disease and gene-expression levels of metalloendopeptidases in human buccal mucosal epithelium.
Tumor necrosis factor-alpha-converting enzyme (TACE) levels in periodontal diseases.
Periodontitis
Periodontal disease and gene-expression levels of metalloendopeptidases in human buccal mucosal epithelium.
Peritonitis
Caught in the act: observation of polymorphonuclear neutrophils for the regulation of tumor necrosis factor-alpha release by tumor necrosis factor-alpha converting enzyme in patients with secondary peritonitis.
In vivo role of leukocyte ADAM17 in the inflammatory and host responses during E. coli-mediated peritonitis.
Neutrophil and macrophage cell surface CSF-1 shed by ADAM17 drives mouse macrophage proliferation in acute and chronic inflammation.
Regulation of peritoneal and systemic neutrophil-derived tumor necrosis factor-alpha release in patients with severe peritonitis: role of tumor necrosis factor-alpha converting enzyme cleavage.
Pneumonia
Abnormal ADAM17 expression causes airway fibrosis in chronic obstructive asthma.
ADAM17 Deficiency Protects against Pulmonary Emphysema.
Examining the Effector Mechanisms of the Feishu Acupoint (BL13) in the Treatment of Pneumonia Based on Systematic Acupuncture and Moxibustion Research.
Leukocyte ADAM17 regulates acute pulmonary inflammation.
Leukocytes require ADAM10 but not ADAM17 for their migration and inflammatory recruitment into the alveolar space.
Lung endothelial ADAM17 regulates the acute inflammatory response to lipopolysaccharide.
Tumor necrosis factor-alpha-converting enzyme: its role in community-acquired pneumonia.
Polycystic Kidney Diseases
A Disintegrin and Metalloenzyme (ADAM) 17 Activation Is Regulated by ?5?1 Integrin in Kidney Mesangial Cells.
A novel inhibitor of tumor necrosis factor-alpha converting enzyme ameliorates polycystic kidney disease.
ADAM17 promotes proliferation of collecting duct kidney epithelial cells through ERK activation and increased glycolysis in polycystic kidney disease.
Transforming growth factor alpha (TGF-alpha) and other targets of tumor necrosis factor-alpha converting enzyme (TACE) in murine polycystic kidney disease.
Polycystic Kidney, Autosomal Recessive
A novel inhibitor of tumor necrosis factor-alpha converting enzyme ameliorates polycystic kidney disease.
Polymyositis
The cell-specific expression of metalloproteinase-disintegrins (ADAMs) in inflammatory myopathies.
Porcine Reproductive and Respiratory Syndrome
Correction for Guo et al., Modulation of CD163 Expression by Metalloprotease ADAM17 Regulates Porcine Reproductive and Respiratory Syndrome Virus Entry.
Modulation of CD163 expression by metalloprotease ADAM17 regulates porcine reproductive and respiratory syndrome virus entry.
Primary Dysautonomias
Activation of ADAM17 (A Disintegrin and Metalloprotease 17) on Glutamatergic Neurons Selectively Promotes Sympathoexcitation.
Prostatic Neoplasms
A novel bispecific single-chain antibody for ADAM17 and CD3 induces T-cell-mediated lysis of prostate cancer cells.
ADAM metallopeptidase domain 17 (ADAM17) is naturally processed through major histocompatibility complex (MHC) class I molecules and is a potential immunotherapeutic target in breast, ovarian and prostate cancers.
ADAM17 regulates prostate cancer cell proliferation through mediating cell cycle progression by EGFR/PI3K/AKT pathway.
ADAM17 targets MMP-2 and MMP-9 via EGFR-MEK-ERK pathway activation to promote prostate cancer cell invasion.
ALCAM/CD166 Is a TGF-?-Responsive Marker and Functional Regulator of Prostate Cancer Metastasis to Bone.
CD82 Suppresses ADAM17-Dependent E-Cadherin Cleavage and Cell Migration in Prostate Cancer.
Inhibition of Notch pathway arrests PTEN-deficient advanced prostate cancer by triggering p27-driven cellular senescence.
[Inhibitory effect of siRNA targeting ADAM17 on the proliferation of prostate cancer PC-3 cells].
Proteinuria
Paricalcitol modulates ACE2 shedding and renal ADAM17 in NOD mice beyond proteinuria.
Psoriasis
Tumor necrosis factor-alpha-converting enzyme as a potential mediator of the influence of smoking on the response to treatment with narrowband ultraviolet B in psoriasis patients.
Pulmonary Arterial Hypertension
Lung ACE2 and ADAM17 in pulmonary arterial hypertension: Implications for COVID-19?
Pulmonary Disease, Chronic Obstructive
ADAM17 and EGFR regulate IL-6 receptor and amphiregulin mRNA expression and release in cigarette smoke-exposed primary bronchial epithelial cells from patients with chronic obstructive pulmonary disease (COPD).
ADAM17 Deficiency Protects against Pulmonary Emphysema.
Expressions of tumor necrosis factor-converting enzyme and ErbB3 in rats with chronic obstructive pulmonary disease.
Role of aberrant metalloproteinase activity in the pro-inflammatory phenotype of bronchial epithelium in COPD.
Pulmonary Emphysema
ADAM17 Deficiency Protects against Pulmonary Emphysema.
ADAM17 protects against elastase-induced emphysema by suppressing CD62L+ leukocyte infiltration in mice.
Pulmonary Fibrosis
ADAM17/EGFR-dependent ERK activation mediates thrombin-induced CTGF expression in human lung fibroblasts.
Renal Insufficiency, Chronic
A Disintegrin and Metalloenzyme (ADAM) 17 Activation Is Regulated by ?5?1 Integrin in Kidney Mesangial Cells.
ADAM17 substrate release in proximal tubule drives kidney fibrosis.
Bradykinin decreases podocyte permeability through ADAM17-dependent epidermal growth factor receptor activation and zonula occludens-1 rearrangement.
iRhom2 promotes lupus nephritis through TNF-? and EGFR signaling.
Role of ADAM17 in kidney disease.
Reperfusion Injury
Effects of PKF242-484 and PKF241-466, novel dual inhibitors of TNF-alpha converting enzyme and matrix metalloproteinases, in a model of intestinal reperfusion injury in mice.
Influences of miR-708 on cerebral ischemia-reperfusion injury through targeted regulation of ADAM17.
Proximal Tubule-Derived Amphiregulin Amplifies and Integrates Profibrotic EGF Receptor Signals in Kidney Fibrosis.
Retinal Neovascularization
Intravitreal injection of TIMP3 or the EGFR inhibitor erlotinib offers protection from oxygen-induced retinopathy in mice.
Pathological neovascularization is reduced by inactivation of ADAM17 in endothelial cells but not in pericytes.
Rhinitis, Allergic
Expression profile of ADAM10 and ADAM17 in allergic rhinitis.
Sarcoma, Synovial
Analysis of mutations in primary and metastatic synovial sarcoma.
Seizures
In pneumococcal meningitis a novel water-soluble inhibitor of matrix metalloproteinases and TNF-alpha converting enzyme attenuates seizures and injury of the cerebral cortex.
Sepsis
Association Study Between Promoter Polymorphisms of ADAM17 and Progression of Sepsis.
Blocking ADAM17 Function with a Monoclonal Antibody Improves Sepsis Survival in a Murine Model of Polymicrobial Sepsis.
Differential effects between marimastat, a TNF-alpha converting enzyme inhibitor, and anti-TNF-alpha antibody on murine models for sepsis and arthritis.
Ectodomain Shedding by ADAM17: Its Role in Neutrophil Recruitment and the Impairment of This Process during Sepsis.
Targeting ADAM17 in leukocytes increases neutrophil recruitment and reduces bacterial spread during polymicrobial sepsis.
TNF? cleavage beyond TACE/ADAM17: matrix metalloproteinase 13 is a potential therapeutic target in sepsis and colitis.
Severe Acute Respiratory Syndrome
ACE2 (Angiotensin-Converting Enzyme 2) in Cardiopulmonary Diseases: Ramifications for the Control of SARS-CoV-2.
Angiotensin-converting enzyme 2 ectodomain shedding cleavage-site identification: determinants and constraints.
MicroRNA?28?3p inhibits angiotensin?converting enzyme 2 ectodomain shedding in 293T cells treated with the spike protein of severe acute respiratory syndrome coronavirus 2 by targeting A disintegrin and metalloproteinase 17.
Shedding Light on COVID-19: ADAM17 the Missing Link?
TMPRSS2 and ADAM17 cleave ACE2 differentially and only proteolysis by TMPRSS2 augments entry driven by the severe acute respiratory syndrome coronavirus spike protein.
Shock, Septic
A disintegrin and metalloproteinase 17 (ADAM17) and epidermal growth factor receptor (EGFR) signaling drive the epithelial response to Staphylococcus aureus toxic shock syndrome toxin-1 (TSST-1).
Critical role of the disintegrin metalloprotease ADAM17 for intestinal inflammation and regeneration in mice.
Plasma soluble Tim-3 emerges as an inhibitor in sepsis: sepsis contrary to membrane Tim-3 on monocytes.
Skin Neoplasms
Differentiation-induced skin cancer suppression by FOS, p53, and TACE/ADAM17.
Spinal Cord Injuries
A disintegrin and metalloprotease 17 promotes microglial cell survival via epidermal growth factor receptor signalling following spinal cord injury.
ADAM17 is a survival factor for microglial cells in vitro and in vivo after spinal cord injury in mice.
ADAM17-deficiency on microglia but not on macrophages promotes phagocytosis and functional recovery after spinal cord injury.
Squamous Cell Carcinoma of Head and Neck
ADAM-17 associated with CD44 cleavage and metastasis in oral squamous cell carcinoma.
ADAM17 mediates OSCC development in an orthotopic murine model.
ADAM17-mediated CD44 cleavage promotes orasphere formation or stemness and tumorigenesis in HNSCC.
Autophagy regulates cisplatin-induced stemness and chemoresistance via the upregulation of CD44, ABCB1 and ADAM17 in oral squamous cell carcinoma.
Involvement of NF-kappaB-mediated maturation of ADAM-17 in the invasion of oral squamous cell carcinoma.
Mass spectrometry-based proteomics revealed Glypican-1 as a novel ADAM17 substrate.
MicroRNA-224, negatively regulated by c-jun, inhibits growth and epithelial-to-mesenchymal transition phenotype via targeting ADAM17 in oral squamous cell carcinoma.
Targeting the sheddase activity of ADAM17 by an anti-ADAM17 antibody D1(A12) inhibits head and neck squamous cell carcinoma cell proliferation and motility via blockage of bradykinin induced HERs transactivation.
Stomach Neoplasms
ADAM-17 expression is enhanced by FoxM1 and is a poor prognostic sign in gastric carcinoma.
ADAM17 promotes epithelial-mesenchymal transition via TGF-?/Smad pathway in gastric carcinoma cells.
ADAM17 promotes lymph node metastasis in gastric cancer via activation of the Notch and Wnt signaling pathways.
Epithelial cell ADAM17 activation by Helicobacter pylori: role of ADAM17 C-terminus and Threonine-735 phosphorylation.
Genotypic and phenotypic characterization of side population of gastric cancer cell lines.
Luteolin alters MUC1 extracellular domain, sT antigen, ADAM-17, IL-8, IL-10 and NF-?B expression in Helicobacter pylori-infected gastric cancer CRL-1739 cells: A preliminary study.
MiR-338-3p inhibits the proliferation and migration of gastric cancer cells by targeting ADAM17.
Prognostic significance of ADAM17 expression in patients with gastric cancer who underwent curative gastrectomy.
Prognostic Significance of ADAM17 for Gastric Cancer Survival: A Meta-Analysis.
Prognostic value of ADAM17 in human gastric cancer.
TGF? induces proHB-EGF shedding and EGFR transactivation through ADAM activation in gastric cancer cells.
Therapeutic potential of ADAM17 modulation in gastric cancer through regulation of the EGFR and TNF-? signalling pathways.
Upregulated Expression of ADAM17 Is a Prognostic Marker for Patients With Gastric Cancer.
Stroke
ADAM17 promotes breast cancer cell malignant phenotype through EGFR-PI3K-AKT activation.
ADAM17 promotes glioma cell malignant phenotype.
Association between ADAM17 Promoter Polymorphisms and Ischemic Stroke in a Chinese Population.
Changes in platelet GPIb? and ADAM17 during the acute stage of atherosclerotic ischemic stroke among Chinese.
Inhibition of ADAM17 reduces hypoxia-induced brain tumor cell invasiveness.
Monocyte-lymphocyte cross-communication via soluble CD163 directly links innate immune system activation and adaptive immune system suppression following ischemic stroke.
Niaspan treatment increases tumor necrosis factor-alpha-converting enzyme and promotes arteriogenesis after stroke.
Telangiectasia, Hereditary Hemorrhagic
Genetic variants of Adam17 differentially regulate TGF? signaling to modify vascular pathology in mice and humans.
Telangiectasis
Genetic variants of Adam17 differentially regulate TGF? signaling to modify vascular pathology in mice and humans.
Tetralogy of Fallot
Substrate-selective protein ectodomain shedding by ADAM17 and iRhom2 depends on their juxtamembrane and transmembrane domains.
Thrombosis
Actin polymerization regulates glycoprotein Ib? shedding.
Which ones, when and why should renin-angiotensin system inhibitors work against COVID-19?
Thyroid Neoplasms
The Putative PAX8/PPAR? Fusion Oncoprotein Exhibits Partial Tumor Suppressor Activity through Up-Regulation of Micro-RNA-122 and Dominant-Negative PPAR? Activity.
Thyroiditis
Elevated MicroRNA-326 Levels Regulate the IL-23/IL-23R/Th17 Cell Axis in Hashimoto's Thyroiditis by Targeting a Disintegrin and Metalloprotease 17.
Tics
miR145 targets the SOX9/ADAM17 axis to inhibit tumor-initiating cells and IL-6-mediated paracrine effects in head and neck cancer.
Trauma, Nervous System
ADAM17-deficiency on microglia but not on macrophages promotes phagocytosis and functional recovery after spinal cord injury.
Triple Negative Breast Neoplasms
ADAM-17: a novel therapeutic target for triple negative breast cancer.
Proteolytic processing of PD-L1 by ADAM proteases in breast cancer cells.
Targeting ADAM-17 with an inhibitory monoclonal antibody has antitumour effects in triple-negative breast cancer cells.
Uremia
ADAM17, a New Player in the Pathogenesis of Chronic Kidney Disease-Mineral and Bone Disorder.
Uterine Cervical Neoplasms
ADAM17 is associated with EMMPRIN and predicts poor prognosis in patients with uterine cervical carcinoma.
Nanoquinacrine sensitizes 5-FU-resistant cervical cancer stem-like cells by down-regulating Nectin-4 via ADAM-17 mediated NOTCH deregulation.
Vascular Diseases
Genetic variants of Adam17 differentially regulate TGF? signaling to modify vascular pathology in mice and humans.
Vascular System Injuries
A disintegrin and metalloprotease 17 mediates neointimal hyperplasia in vasculature.
Ventilator-Induced Lung Injury
Hypercapnia attenuates ventilator-induced lung injury via a disintegrin and metalloprotease-17.
Virus Diseases
ADAM17 is an essential attachment factor for classical swine fever virus.
Does Angiotensin II Peak in Response to SARS-CoV-2?
Metalloprotease ADAM17 regulates porcine epidemic diarrhea virus infection by modifying aminopeptidase N.
Tetraspanin CD9 affects HPV16 infection by modulating ADAM17 activity and the ERK signalling pathway.